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ABSTRACT
DESIGN AND SYNTHESIS OF BENZIMIDAZOLES AS CDK5 INHIBITORS AND
PROGRESS TOWARD THE TOTAL SYNTHESIS OF TUBULYSIN D

By
Shuyan Yi
May 2009

Thesis supervised by Dr. Patrick T. Flaherty
This thesis describes the design and synthesis of 1,4,6-trisubstituted
benzimidazoles as CDK5 inhibitors and the progress toward the total synthesis of
tubulysin D.
Tubulysin is a natural product with potential anti-cancer activity. The two γ-amino acids
in Tuv and Tup fragments of the tubulysins were synthesized. Evans’ oxazolidinone
chemistry was employed for the stereoselectively synthesis of Cbz-β-homovaline in Tuv
fragment. A crystal structure of the Tup fragment was obtained.
Cyclin dependent kinase 5 (CDK5) is one of the kinases that can hyperphosphorylate tau.
Selective inhibition of the CDK5/p25 complex may be a useful component for
Alzheimer’s disease therapy. Benzimidazole based analogs of the known non-selective
CDK5 inhibitor (R)-Roscovitine were designed. Synthesis of 6-benzyl substituted
benzimidazole analogs was developed and two compounds were synthesized in this
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series. Two methods of the synthesis of 6-(2-hydroxy-1-alkyl)amino substituted
benzimidazole analogs were developed.

v

ACKNOWLEDGEMENT

I would like to expecially thank Dr. Patrick T. Flaherty for bringing me to the research
group, being my thesis advisor, encouraged, and supervised my research.
I thank Dr. Aleem Gangjee, Dr. David J Lapinsky, Dr. Marc W. Harrold for teaching me
the course work, and being my committee member. I appreciate the valuable suggestions
from them.
I thank my labmates Prashi Jain and Ishveen Chorpra. I had a pleasant time working with
them. I also thank all my colleagues in medicinal chemistry.
I also thank Dr. Laurent Meijer for the biological testing and Dr. Omar Stewart for
providing the X-ray analysis of the crystal structure.
Finally, I wish to express my love and gratitude to my beloved husband Yiqiang Wang
and my parents; for their understanding & endless love, through the duration of my
studies.
This work is supported by the following grants:
•

CDK5: National Institute of Health (NINDS): 1R15NS057772

•

Tubulysin: Duquesne University Faculty Development Fund: 04-630842

•

NMR: National Science Foundation: NMR: CHE0614785

vi

TABLE OF CONTENTS
Page
Abstract .............................................................................................................................. iv
Acknowledgement ............................................................................................................. vi
List of Tables ................................................................................................................... viii
List of Figures .................................................................................................................... ix
List of Schemes.................................................................................................................. xi
List of Abbreviations ....................................................................................................... xiii
Biological Literature Review ..............................................................................................1
Chemical Literature Review ..............................................................................................39
Statement of the Problem...................................................................................................53
Chemical Discussion..........................................................................................................59
Summary ............................................................................................................................73
Experimental ......................................................................................................................76
Bibliography ....................................................................................................................106
Appendix..........................................................................................................................113

vii

LIST OF TABLES
Page
Table 1. Selected Microtubule-targeted drugs and their binding sites on tubulin...............7
Table 2. Selected CDK inhibitors .....................................................................................35
Table 3. Basic pKa values of benzimidazoles ...................................................................47
Table 4. Biological activity of the initial series of benzimidazoles synthesized...............58
Table 5. Coupling reaction for C6-C bond formation........................................................68
Table 6. Results by Analysis with the Madura scoring algorithm ..................................113
Table 7. New scoring results ...........................................................................................116

viii

LIST OF FIGURES
Page
Figure 1. Polymerization of microtubules...........................................................................3
Figure 2. Human osteosarcoma cells in different stages of the cell cycle with and without
addition of antimitotic drugs................................................................................................5
Figure 3. Structure of tubulysins.......................................................................................10
Figure 4. Structure of tubulysin A ....................................................................................11
Figure 5. Molecular comparison of the dolastatins and tubulysins...................................12
Figure 6. SAR of dolastatin 10 and 15............................................................................15
Figure 7. Known SAR of tubulysin ..................................................................................17
Figure 8 Modification of the C-terminus of tubulysin D by Ellman’s group ...................18
Figure 9. Classification of human protein kinases based on sequence and structure .......20
Figure 10. Functions of CDKs ..........................................................................................21
Figure 11. Cleavage of p35 to p25....................................................................................25
Figure 12. Intracellular neuronal aggregates in tauopathies .............................................26
Figure 13. Ribbon diagram of the CDK5/p25 complex .................................................27
Figure 14. Binding modes of kinase inhibitors .................................................................29
Figure 15. Purine CDK inhibitors .....................................................................................31
Figure 16. Pyrimidine CDK inhibitors..............................................................................32
Figure 17. Oxindole CDK inhibitors.................................................................................32
Figure 18. Other heterocyclic templates ...........................................................................33
Figure 19. Flavonoids and Stauosporine derivatives ........................................................33
Figure 20. Structure of (R)-roscovitine, aloisine-A, and indirubin-3’-oxime ...................34

ix

Figure 21. Structre of compound 33-35 ............................................................................36
Figure 22. Aligned overlay of CDK5 and five inhibitors .................................................37
Figure 23 CDK5 inhibitors from Pharmacia.....................................................................37
Figure 24. CDK5 inhibitors from Pfizer ...........................................................................38
Figure 25. CDK5 inhibitors from Amgen.........................................................................38
Figure 26. Structure of 1H-Benzimidazole .......................................................................46
Figure 27. Desired SAR points of benzimidazole based (R)-roscovitine analogs ............49
Figure 28. Possible modifications in Tuv fragment of tubulysin......................................53
Figure 29. Target compounds of the 6-benzylbenzimidazole series................................54
Figure 30. Structural analysis of (R)-roscovitine-CDK5/p25 (PDB ID: 1UNL)..............55
Figure 31. Structural changes to (R)-roscovitine ..............................................................56
Figure 32. Structure analysis of (R)-roscovitine-CDK2 (PDB ID: 2A4L). .....................56
Figure 33. Target compounds of 6-aminobenzimidazole series .......................................57
Figure 34. Proposed interactions of compounds 120a and 120b with CDK5/p25 .........114
Figure 35. Proposed interactions of compounds 173a,b and 181c with CDK5/p25 ......117
Figure 36. The ORTEP drawing of the X-ray crystal structure of compound 146a.......118

x

LIST OF SCHEMES
Page
Scheme 1. Synthesis of Tuv fragment by Höfle et al. ......................................................40
Scheme 2. Synthesis of Tup fragment by Höfle et al. . ....................................................40
Scheme 3. Multicomponent synthesis (Morphochem) of the Tuv fragment. . .................41
Scheme 4. Retro synthesis of Tup fragment by Morphochem in patent. . .......................41
Scheme 5. Retro synthesis of Tup fragment by Morphochem published. . ......................42
Scheme 6. Wifp’s initial synthesis of Tuv fragment. . .....................................................42
Scheme 7. Wifp’s second synthesis of Tuv fragment. . ...................................................43
Scheme 8. Wifp’s synthesis of Tup fragment. ................................................................43
Scheme 9. Ellman synthesis of Tubulysin D. . .................................................................44
Scheme 10. 1,3-Tetrahydrooxazine stragety for protection of 1,3-alcohol in Tup ...........45
Scheme 11. The key step in Fecik’s synthesis of Tuv fragment. . ...................................45
Scheme 12. The key step in Fecik’s synthesis of Tup fragment. . ...................................45
Scheme 13. Formation of 1-2 and 2-3 bonds in benzimidazoles. . ..................................48
Scheme 14. An example of formation of 1-2 or 2-3 bonds in benzimidazoles. . .............49
Scheme 15. Synthesis of 5,7-disubstitued 1H-benzo[d]imidazole-2-thiol. .....................50
Scheme 16. Synthesis of 6-methoxy-4-nitro-1H-benzo[d]imidazole. . ...........................50
Scheme 17. Synthesis of 4,6-dichloro-1H-benzo[d]imidazole. . ......................................51
Scheme 18. Synthesis of 6-iodo-N,N-dimethyl-4-nitro-1H-benzo[d]imidazol-2-amine. . 51
Scheme 19. Synthesis of 1-methyl-2-(trichloromethyl)-1H-benzo[d]imidazole. . ...........52
Scheme 20. Reaction of 2-nitroanilines with carboxylic acids and ortho esters. . ...........52
Scheme 21. Benzimidazole formation from N1, N1-disubstitued 1,2-diaminoarenes. . ....52

xi

Scheme 22. Overall strategy of tubulysin synthesis. . ......................................................60
Scheme 23. Synthesis of Tuv fragment. . .........................................................................61
Scheme 24. Synthesis of Tup fragment. . .........................................................................62
Scheme 25. Synthesis of compound 143 by DIBAL-H reduction. . ................................63
Scheme 26. Synthesis of compound 70 with Horner-Wadsworth-Emmons strategy. . ...63
Scheme 27. Synthesis of 5-methoxy-7-nitro-1H-benzo[d]imidazole. . ............................64
Scheme 28. Initial synthsis of compound 152a in our lab. . ............................................64
Scheme 29. Dirrect N1-alkylation of preformed benzimidazole 99. . ..............................65
Scheme 30. Improved synthesis of 1-isopropyl-6-methoxy-4-nitro-1Hbenzo[d]imidazole. . ..........................................................................................................65
Scheme 31. 6-Alkyl substitution by method A. . .............................................................66
Scheme 32. Synthesis of compound 162. . ......................................................................67
Scheme 33. 6-Benzyl substitution by method B. . ...........................................................69
Scheme 34. 6-Amino substitution by Method C. . ...........................................................70
Scheme 35. 6-Amino substitution by Method D. . ...........................................................72

xii

LIST OF ABBREVIATIONS

MAPs

microtubule associated proteins

AD

Alzheimer's Disease

MDR

multidrug resistance

TGI

total growth inhibition

CYPs

Cytochrome P450

Pgp

P-glycoprotein

Tuv

tubuvaline

Tup

tubuphenylalanine

Tut

tubutyrosine

CDKs

cyclin-dependent kinases

CAKs

CDK-activated kinases

NFTs

neurofibrillary tangles

Pi

inorganic phosphate

Mep

N-methyl pipecolic acid

Ile

isoleucine

Tuv

tubuvaline

Tut

tubutyrosine

Tup

tubuphenylalanine

CNS

central nervous system

HTS

high throughput screen

xiii

Chapter 1
Biochemical Literature Review
1.1 Introduction
Microtubules are filamentous heteroprotein polymers that form one of the major components of
the cytoskeleton. They serve as structural components within cells and are involved in many
cellular processes including mitosis, cellular motility, cellular structure and cytoplasmic
transport. Microtubules are composed of α-and β-heterodimers, although species-specific
isoforms exist. Microtubules undergo cycles of rapid assembly and disassembly in a process
known as dynamic instability. Microtubule associated proteins (MAPs) bind to the tubulin and
regulate microtubule stability. Their binding can be regulated by phosphorylation by kinases.
The highly dynamic microtubules are extremely important in mitosis, during which the
duplicated chromosomes of a cell are separated into two identical sets before division of the
parent cell into two daughter cells. Inhibition of mitosis is a powerful strategy for treating
diseases associated with excessive cell proliferation. Thus tublin-interacting drugs perturb
microtubule dynamics, can cause mitotic block, and cause subsequent apoptosis are widely used
for the treatment of cancer.
While perturbing microtubule dynamics may lead to cell apoptosis or death, the abnormality of
MAPs can also change the stability of microtubules, leading to certain diseases. In particular,
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tau protein, an MAP, exclusively expressed in neurons, normally binds to tubulin and stabilizes
microtubules, thus maintaining the integrity of neural cytoskeletal structure. In Alzheimer’s
disease (AD), tau protein is abnormally hyperphosphorylated and dissociates from microtubules,
leading to destabilization of microtubules, which contributes to the disease state. Further
evidence of this is that the neurofibrillary tangles (NFTs) contain the form of tau uniquely
phosphorylated by cyclin dependent kinase 5 (CDK5). CDK5 co-localizes with NFTs in AD and
other neurodegenerative diseases. Thus blocking tau pathology may be a useful component in
AD therapy.

1.2.1 Tubulysin
1.2.1.1 Microtubules
Microtubules-the key component of cytoskeleton- are cylindrical protein filaments found in all
eukaryotes. They are crucial in the development and maintenance of cell shape and cell
function. They are also critically involved in a variety of cellular processes including cellular
motility, cytoskeletal structure, cytoplasmic transport and mitosis.
Microtubules are composed of α-tubulin and β-tubulin heterodimers. Each individual tubulin
heterodimer (typical dimensions: 4 nm × 5 nm ×8 nm) interacts laterally and longitudinally to
form protofilaments and then aggrate microtubules that can be many micrometers long. An
interesting feature of tubulin is its presence as multiple isoforms in eukaryotic organisms and its
numerous post-translational modifications, including phosphorylation, acetylation,
detyrosination and polylutamylation. 1, 2

2

Microtubule polymerization dynamics
The biological functions of microtubules are achieved by their polymerization dynamics. The
polymerization of microtubules start with slow formation of a short microtubule “nucleus”
followed by the rapid elongation at either end of the microtubules by the reversible, noncovalent
addition of the tubulin heterodimers (Figure 1).

Figure 1. Polymerization of microtubules3.

Microtubules exhibit two kinds of interesting non-equilibrium dynamic behaviors, namely
“dynamic instability” and “treadmiling”. In dynamic instability, the individual microtubule ends
switch between phases of growth and shortening. The two ends of a microtubule designated
“plus end” and “minus end” are not equivalent. The plus end is capped with α-tubulin, the minus
end with β-tubulyn. The plus end grows and shortens more rapidly and more extensively than
the minus end. Microtubules may undergo relatively long periods of slow growth, brief periods
of rapid shortening, and periods of pause, when the microtubules neither grow nor shorten
detectably. The four parameters that characterize microtubule dynamic instability are: the rates
of microtubule growth and shortening and the frequencies of “catastrophe” and “rescue”.
3

Catastrophe refers to the rapid transition from growth or pause to shortening, while rescue refers
to the rapid transition from shortening or pause to growth.
The second dynamic behavior, treadmilling, consists of growth at one end of a microtubule and
balanced shortening at the other end. The net result is an orderly flow of tubulin α and β
subunits from the plus end of the microtubule to the minus end.
The polymerization dynamics of microtubules are moderated by the gain and loss of the GTPcap at ends of microtubules. The GTP cap is a short region of tubulin-GTP or tubulin-GDPinorganic phosphate (Pi). When the tubulin dimer with GTP bound to β-tubulin adds to one end
of the microtubule, GTP is hydrolyzed to GDP at the same time or shortly thereafter. Thus
tublin-GDPs are incorporated into the microtubules, leaving the end of the microtubule covered
by the GTP-cap. With the presence of the GTP- cap, the microtubule is stable, and the end can
grow; 4 when the GTP-cap is lost, the tubulin-GDPs are exposed, and the microtubule rapidly
undergoes depolymerization.
Microtubule dynamics are regulated by a myriad of mechanisms in the cells, including tubulin
isotype expression, post-translational modification of tubulin, microtubule-associate proteins and
microtubule-interacting proteins.
Microtubule dynamics speed up dramatically in mitosis
Mitosis is a critical stage in the cell cycle. During mitosis, replicated chromosomes are
segregated to opposite poles of a dividing cell, followed by cell division to yield two daughter
cells. The mitotic spindle is the central component of mitosis. The microtubules in mitotic
spindles have uniquely rapid dynamics. They are 4 – 100 times more dynamic than the
microtubules in the interphase cytoskeleton. 5, 6
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The highly dynamic microtubules are essential to all stages of mitosis (Figure 2). During
prometaphase, microtubules emanating from each of the two spindle poles dynamically probe the
cytoplasm, find chromosomes, and attach to the kinetochores.7 For microtubules to find
chromosomes and attach successfully, they must be able to grow and shorten rapidly and over
long distances. The failure of a single chromosome to achieve a kinetochore attachment to the
spindle is sufficient to trigger mitotic rest and apoptosis.8 Many microtubule-targeted anticancer drugs act at this stage.

Figure 2. Human osteosarcoma cells in different stages of the cell cycle with and without addition of
antimitotic drugs.3 Microtubules are shown in red, chromosomes in blue and kinetochores in green. a.
In prometaphase, microtubules have emanated from the two spindle poles, and in the process of finding
and attaching to the kinetochores. b. In metaphase, duplicated chromosomes have migrated to the
equatorial centerplate. c. In anaphase, the duplicated chromosomes have separated and are moving
towards the spindle poles d. In telophase, the separated chromosomes have reached the spindle poles.
e. In the presence of 10 nM paclitaxel, some chromosomes remain at the spindle poles and have not
migrated to the centerplate in metaphase. f. Similarly, in the presence of 50 nM vinflunine, some
chromosomes remain at the spindle poles.

During metaphase, duplicated chromosomes migrate to the equatorial centerplate and are under
high tension. They oscillate back and forth across the spindle midline; the tension is produced
5

by both microtubule treadmilling and dynamic instability.9 The oscillation of chromosome pairs
arises from the alternative growing and shortening of the microtubules attached to sister
kinetochores. In anaphase, microtubules attached to chromosomes must undergo a carefully
regulated shortening to separate the chromosomes and then move to the two spindle poles.
In summary, the rapid dynamics of microtubules are crucial for mitosis; suppression of
microtubule dynamics by drugs induce mitotic rest and apoptosis. This has been realized as a
useful strategy in the treatment of cancer. One reason that many cancer cells are relatively more
sensitive to these drugs compared to many normal cells is that the more frequently dividing
cancer cells pass through the vulnerability mitotic process more frequently and are more
susceptible to mitotic poisons.

1.2.1.2 Tubulin interacting antimitotic drugs
A variety of substances originating from natural products bind to soluble tubulin and/or different
sites on tubulin in previously polymerized microtubules with different affinity and reversibility.
These substances affect microtubule dynamics. Many of them are antimitotic agents and used
clinically (Table 1).10
Classification
According to their effect on microtubule polymerization upon binding, the tubulin interacting
agents fall into two classes: microtubule stabilizing agents and microtubule destabilizing agents.
The microtubule stabilizing agents stimulate a net microtubule polymerization and include taxol
(Taxol®, the first identified in this class), docetaxel (Taxotere®), the epothilones, ixabepilone,
discodermolide, the eleutherobins, sarcodictyins, laulimalide, rhazinalam, and certain steroids
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and polyisoprenyl benzophenones.
Table 1. Selected Microtubule‐targeted drugs and their binding sites on tubulin10.
Binding
domains

Drugs

Therapeutic uses

Vinca
Domain

Vinblastine (Velban)
Vincristine (Oncovin)
Vinorelbine (Navelbine)
Vinflunine
Dolastatins
Hemiasterlins (HTI‐286)

Hodgkin’s disease, testicular germ cell cancer
Leukemia, lymphomas
Solid tumors, lymphomas, lung cancer
Bladder, non‐small cell lung cancer, breast cancer
Vascular targeting agents

Colchicine
Colchicine
Domain

Combretastatins
2‐Methoxyestradiol
Methoxybenzene‐sulfonamide
Diketopiperazine (NPI‐2358)
Paclitaxel and analogs

Taxane
Site
Other
Binding
Sites

Docetaxel (Taxotere)
Epothilone
Discodermolide
Estramustine
Arsenic trioxide
Noscapine

Non‐neoplastic diseases (gout, familial
Mediterranean fever), also actinic keratoses
Vascular ‐disrupting agents
Multiple myeloma, glioblastoma multiforme
carcinoid, prostate, breast
Solid tumors, vascular‐disrupting agents
Vascular‐disrupting agent
Ovarian, breast, lung tumors, Kaposi’s sarcoma;
trials with numerous other tumors
Prostate, brain, breast, and lung tumors
Taxol‐resistant tumors
Synergistic with taxanes
Prostate, often in combination
Vascular‐disruptive agent
Leukemia, lymphoma

The microtubule destabilizing agents inhibit net microtubule polymerization, and include the
Vinca alkaloids (vinblastine, vincristine, vinorelbine, vindsine, and vinflunine), halichondrins,
hemiasterlins, dolastatins, maytansine alkaloids, estramustine, 2-methoxyestradiol, colchicine,
the anti-tussive noscapine and its analogs, diketopiperazine, and the combretastatins.
Additionally, this group includes a very large number of natural compounds that have not
undergone clinical development for cancer therapy, including rhizoxin, spongistatins,
podophyllotoxin, steganacins, curacins, and others.
These agents can also be classified by their binding sites on tubulin and microtubules (Table 1).
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The four most common binding domains are the Vinca domain (including Vinca site and peptide
binding site), the colchicine domain, the taxane site, and the GDP/GTP binding site. Other
binding sites are also observed.
A principal antimitotic mechanism of tubulin-interacting drugs is suppression of
microtubule dynaymics.
Despite the terms “depolymerizing” and “polymerizing” used for the classification, the two
classes of agents both stabilize microtubules kinetically at lower concentrations. At such
concentrations, the generated microtubules mass neither increases nor decreases. As previously
described, the mitotic spindle requires highly dynamic microtubules to function timely and
spaciously. Suppression of microtubule dynamics by sequestration into less dynamic forms is an
efficient way to inhibit cell proliferation. The Vinca alkaloids are example11. The Vinca
alkaloids depolymerize microtubules and destroy mitotic spindles at high concentrations (10 –
100 nM in HeLa cells), while at low - but clinically relevant concentrations - vinblastine does not
depolymerize spindle microtubules, yet powerfully blocks mitosis and causes apoptosis (IC50 0.8
nM in HeLa cells). Further, the generation of “paracrystals” is a unique and often diagnostic test
for activity at the Vinca binding site.
Anti-angiogenic and vascular-disrupting mechanisms of tubulin-interacting drugs
The tumor vasculature is also an attractive target for cancer therapy. Endothelial cells do not
have the ability to create drug resistance as tumor cells do. The two approaches to inhibit
vascular function are to inhibit the formation of new host vasculature by anti-angiogenic agents
or to attenuate the existing vasculature by the use of vascular-disrupting agents.12, 13 Although
there are specific anti-vascular drugs, many classical tubulin-interacting agents also modify
8

vasculature in animals.14 This anti-angiogenic effect may contribute to their anti-cancer profile in
vivo.
Limitations of tubulin-interacting anti-proliferation agents
One of the greatest limitations of cancer chemotherapy of the tubulin-interacting agents is the
development of the multidrug resistance (MDR) phenotype. MDR is often mediated by overexpression of a class of transmembrane transporter proteins known as ABC-tranporters (ATPdependent drug efflux pumps). They effectively pump hydrophobic compounds, including drugs
out of the cell, and decrease intracellular drug concentration. One characteristic of these
transporters is that they can transport very different chemical structures, such as paclitaxel and
the Vinca alkaloids. P-glycoprotein was the first transport protein identified and is still one of
the most important ABC-transporters. Research on the understanding the mechanism of its
action and the development of P-glycoprotein inhibitors, and the development of tubulininteracting agents that are non-P-glycoprotein substances are underway. Other mechanisms of
MDR include over-expression of key proteins involved in initiating apoptosis, post-translational
modifications and expression of different tubulin isotypes. The clinical utility of the tubulininteracting agents is further limited by their poor pharmacokinetics and therapeutic index.

1.2.2 Tubulysin
1.2.2.1 Discovery and structure identification
Tubulysins are a family of novel peptide based antibiotics isolated from various Myxobacteria
species.15 They were discovered by Reichenbach and Höfle research groups at the Gesellschaft
für Biotechnologische Forschung (GBF). Tubulysins were identified by bio-assay-directed
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screening of the fermentation broth of Archangium gephyra and Angiococcus disciformis. A.
gephyra produces tubulysins A, B, C, G, and I all of which have a p-hydroxyphenyl residue. A.
disciformis produce the unsubstituted phenyl analogs of tubulysins: D, E, F, and H. Tubulysin A
was the major component produced during small scale or production fermentation.

Tubulysin

R1

R2

R3

A
B
C
D
E
F
G

CH2O(CO)CH2CH(CH3)2
CH2O(CO)CH2CH2CH3
CH2O(CO)CH2CH3
CH2O(CO)CH2CH(CH3)2
CH2O(CO)CH2CH2CH3
CH2O(CO)CH2CH3
CH2O(CO)CH=C(CH3)2

OH
OH
OH
H
H
H
OH

Ac
Ac
Ac
Ac
Ac
Ac
Ac

H
I
…
U
V
…
Z

CH2O(CO)CH3
CH2O(CO)CH3

H
OH

Ac
Ac

H
H

H
H

Ac
H

H

OH

H

Figure 3. Structure of tubulysins.

The structure and absolute configuration of tubulysins were established by chemical degradation
and comparison to the corresponding natural and unnatural amino acids, NMR analysis, and the
X-ray crystal structure of tubulysin A.16 They are linear tetrapeptides composed of N-methyl
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pipecolic acid (Mep), isoleucine (Ile), a novel amino acid named tubuvaline (Tuv), and a novel
chain-extended tyrosine analogue named tubutyrosine (Tut) or the phenylalanine analogue
named tubuphenylalanine (Tup). In tubulysin A – I the N-acyloxymethy substituent varies in
size. This substituent may also be regarded as a formyl N,O-acetals; formaldehyde was liberated
upon acidic hydrolysis. Tubulysins without the N-acyloxymethyl substituent appeared in
Dömling’s paper17 and more recently in other publications18, 19 as well.

a

b

Figure 4. Structure of tubulysin A16. a. Stereoview of the crystal structure of tubulysin A (ORTEP plot,
hydrogen atoms added). b. Comformation of tubulysin A in [D6]DMSO, based on the crystal structure,
NOE correlations, and vicinal proton coupling constants. Ac = acetyl.
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The structure of tubulysin A in X-crystal structure and in DMSO (Figure 4) both identify
rotation about the thiazole ring. The Tuv side of the thiozole ring is relatively crowd. To place
the hydrophobic substituents into different orientations, the conformation is almost set for this
side.
Interestingly, the overall chemical structure of tubulysins resembles those of the dolastatins
(Figure 5).20 Comparisons have been published.20 Both have a tertiary amine at the N-terminus
an aromatic side chain at the C-terminus. Moreover, the left- and right-hand sides in both
compound classes are separated by 18 to 21 bonds with a distance of approximately 16 – 18 Å.
Both classes present exclusively hydrophobic side chains, and both adopt low energy bent
conformation adjacent to the central heterocyclic region.

Figure 5. Molecular comparison of the dolastatins and tubulysins.20 The geometry‐optimized models
give a distance between the N‐terminal nitrogen and the C‐terminal ipso‐aryl carbon of tubulysin D,
dolastatin 10 and dolastatin 15 of 16.4, 17.0 and 18.4 Å, respectively.
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1.2.2.2 Biological evaluation
The Höfle group did some initial biological evaluation of tubulysins A – I16 and found they were
extremely potent cytotoxic agents with IC50 in the subnanomolar range against the L929 cell line;
this is comparable to dolastatin 10 and is more potent than vinblastine. The author claimed that
intracellular concentration of the tubulysins remains high in the MDR cell line. They also found
that there is a strong correlation between cellular activity and the lipophilicity of the
corresponding tubulysin form tested. These derivatives showed more or less the same activity to
inhibit tubulin polymerization in vitro, suggesting that the difference in the cellular activity
comes results from preferential uptake of the lipophilic tubulysins from the medium by the cells.
Because tubulysin A is the most available from the natural sources, further biological studies
were conducted on tubulysin A. The mechanism of action of tubulysins was examined in several
assays by the Reichenbach and Höfler group21:
a. In cell culture analysis, tubulysin A led to depletion of microtubules within the cells,
which could not be blocked by microtubule stabilizing agents such as epothilone B or
paclitaxel. Tubulysin A induced apoptosis and cell accumulation in the G2/M phase of
the cell cycle. These results show that tubulysin A interferes with microtubule dynamics,
and may act as an antimitotic drug inducing apoptosis.
b. In vitro, tubulysin A inhibited the polymerization of tubulin at substoichiometric doses,
and the efficacy of inhibition was comparable to that of phomopsin A; vinblastine was
less efficacious.
c. Binding competition experiments showed that tubulysin A inhibit the binding of
vinblastine to tubulin in a non-competitive manner, indicating that tubulysin A binds to a
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portion of Vinca domain of β-tubulin, but perhaps not the entire site.
d. Using electron microscopy, oligomeric tubulin aggregates form rings, double rings and in
the presence of MAPs, pinwheel-like structures were observed at substoichiometric
concentrations of tubulysin A. These aggregates most closely resemble the tubulin rings
of dolastatin22 and phomopsin23, suggesting a similar site of interaction with tubulin.
The biological evaluation of tubulysin A by the group from Morphochem AG led by Doemling
focused on potency in MDR cell lines, selectivity over normal cells, metabolic stability,
antiangiogenic activitity, and in vivo efficacy.24 These properties are important components to
evaluate for potential clinical use as anticancer and antiangiogenic agents:
a. In the NCI 60-human cell line screen, tubulysin A was too potent to reliably calculate a
GI50. Tubulysin A showed a distinct pattern for total growth inhibition (TGI) for a panel
of melanoma, leukaemia and prostate cancers suggesting specificity for certain tumor
types.
b. The activity of tubulysin A (GI50 0.059 ± 0.03 nM) to inhibit cell growth surpassed that
of paclitaxel (GI50 1.95 ± 1.04 nM) and vinblastine (GI50 0.94 ± 0.51 nM) against the HL60 cell line. Moreover, comparable activity against HCT-116 (non-MDR resistant cell
line with very low Pgp expresstion) and HCT-15 (cell line with very high Pgp
expresstion) cells showed that tubulysin A is not a substrate of Pgp.
c. The Morphochem group also observed that there is at least a 10-fold difference in the
induction of apoptosis in cancer cell (HL-60) versus normal cell (HUVEC). The standard
compounds paclitaxel and vinblastine showed no selectivity between the two cell lines.
d. Tubulysin A showed a low potential for interaction with the three major CYPs (CYP1A2,
3A4, and 2D6).
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e. In HUVEC-based in vitro assays, tubulysin A showed similar IC50 values for both cord
formation and cell migration, compared to the data of paclitaxel and a second small
molecule inhitibitor of tubulin dynamics, TNP-470. Thus tubulysin A has the potential
for significant anti-angiogenic activity in vivo.
f. In the hollow fibre assay, a preliminary in vivo assay, tubulysin A inhibited cell growth in
33% of the 12 cancer cell lines tested, which places tubulysin A among the top 5% of
3290 compounds ever tested at the NCI.
In conclusion, both in vitro and in vivo assays suggest that tubulysin A is a potent
antiproliferative agent, with in vivo and potential antiangiogenic activity.

1.2.2.3 SAR of dolastatins

Figure 6. SAR of dolastatin 10 and 15.25
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Considering the structure and bind mode resemblance of tubulysin to dolastatin, a brief summary
of the SAR of dolastatin 10 and 15 is presented here, but presented in greater detale eswhere.25
A summary of the most relevant SARs points is as follows:
a. Essential requirement for a basic amine at the N-terminus.
b.

Wide latitude for hydrophobic side chain replacement.

c. A phenylethyl substitution on the C-terminus is optimal; the C-terminal portion is not

very sensitive to structural modification.

1.2.2.4 Known SAR of tubulysins and their analogs
The groups led by Peter Wipf26, Jonathan A. Ellman27, and Robert A. Fecik18, 28, 29 respectively
have synthesized several analogs of tubulysin. The SARs summarized here combines the studies
of all three groups. The following points are worth remembering prior to cross analysis:
a. Different cell lines and experimental conditions were used by different groups; this may
complicate direct comparisons.
b. Different standard compounds were used for the tubulysin analog assay; again, crossgroup comparison may be difficult.
c. Cellular assays and in vitro tubulin depolymerization assays do not always show the same
trend within a given group of compounds. (The Ellman group did not do an in vitro
tubulin depolymerization assay.) In general, the activity in cell-based assay is more
sensitive to structural modification; lipophilic compounds tend to be more potent in these
assays. The tubulin depolymerization assay is a direct in vitro assay and is less affected
by lipophilic effects. The reason for this is not clear; one possible explanation is that the
lipophilicity may contribute to cellular uptake properties.
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d. Only Ellman’s group developed the total synthesis of tubylysin D which has the N,Oacetal substitution. Ellman’s analogs have only one point variation based on tubulysin D.
Wipf’s analogs all have an N14-methyl substituent. Fecik’s analogs have no substituent
on N14 and part D is further altered by the incorporation of a ketone.
The SAR was studied on several parts of the molecule: (Figure 7)

Figure 7. Known SAR of tubulysin.

Part A: This is the most interesting modification part because the natural substituent is
chemically labile, causing synthetic difficulties for tubulysin and biological instabilities of
tubulysin analog testing.
•

N-methyl substitution: results in a minimal drop of activity as compared to tubulysin D27;
the compound activity is comparable to that of vinblastin and paclitaxel.

•

No N-substitution: according to Domling17 (data not published), tubulysin U and V,
which have no substituent, are less active than tubulysin A – I, but again they are within
the activity range of taxol and epothilones. However, Fecik’s group showed that
tubulysin U is extremely potent: subnanomolar activity against the 1A9 and MCF-7 cell
lines.19
17

•

Other N-substituents: alkyloxy, alkylthio, amido, acyloxy, or simply an alkyl substituted
analogs inhibited the growth of KB cells in a dose-responsive manner with an IC50 in the
lower nanomolar range.30

Part B:

Figure 8 Modification of the C‐terminus of tubulysin D by Ellman’s group.

A wide range of modifications are tolerated according to Ellman.27 The following modifications
result in less than a 2 fold drop in activity compared to tubulysin D. This suggests that part B
may be used to modify pharmacokinetic properties of the drug.
Part C:
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All three groups show that replacement of Mep with a simple tertiary amine is well tolerated.
Ellman’s compound 2 was equipotent to tubulysin D27 while the other two groups showed some
decrease in activity in cellular assay.26, 29
Part D:
•

Replacement by hydroxyl: Ellman’s compound 3 showed a modest decrease in activity
compared to tubulysin D.27 Fecik showed that tubulysin V (R2 = H) is 1000 fold less
potent than tubulysin U (R2 = H).18 Fecik also made epi-tubulysin V, which is less potent
than tubulysin V in the cellular assay; while the in vitro tubulin depolymerization assay
gave an equivalent result for the two epimers.18

•

Stereochemistry of the 7-hydroxyl group: Wipf’s N14-methyl analogs showed that the two
epimers are equipotent in the cell-based assay, while R configuration is preferred in
tubulin depolymerization assay.26

•

Replacement by ketone: this modification (Fecik) removes one stereoceter, results in
dramatic loss of activity compared to tubulysin U.18,29

1.3 Cyclin-dependent kinases
1.3.1 Pharmacology
1.3.1.1 Kinases: an overview
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There are 518 kinases encoded by the human genome and these sequences constitute about 2%
of the known human genes.31 They can be grouped into a number of subsets based primarily on
sequence and structural similarities (Figure 9). In general, protein kinases catalyse the transfer

Figure 9. Classification of human protein kinases based on sequence and structure. The numbers refer to
number of protein kinases in each subset. Note that CMGC includes CDK.

of the terminal phosphoryl group from ATP to an acceptor hydroxyl group of serine, theronine,
or tyrosine residue on their protein substrates. These enzymes regulate the majority of signal
transduction pathways in cells, and thus have an important role in cell growth, metabolism,
differentiation, and apoptosis.
Deregulation of protein kinases is implicated in a number of diseases including cancer, diabetes,
and inflammation. Targeted inhibition of protein kinases has thereby become an attractive
therapeutic strategy in the treatment of relevant diseases.33, 34

1.3.1.2 Cyclin-dependent kinases: an overview
Cyclin-dependent kinases (CDKs) are Ser/Thr kinases. As suggested by their name, the CDKs
associate with a regulatory parter (i.e. cylin or other protein) for activation. 13 CDKs and 25
proteins with high homology to cyclin proteins are encoded within the human genome.
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Figure 10. Functions of CDKs. 35 Transcription (brown), neurones (cyan), differentiation (orange), cell
death (black) or other events (purple)35. *VDCC, voltage‐dependent Ca2+ channel.

Although CDKs were initially studied for their cell cycle function, it was later discovered that
some members of the CDK family have different functions (Figure 10)35. CDKs 1, 2, 3, 4, and 6
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play essential functions in cell cycle control. CDKs 7, 8, 9, and 11 regulate transcription. CDK5
has numerous roles in the nervous system and modifies cell fate and cell morphology.
The activity of CDKs is tightly controlled at many mechanisms36, 37:
a. Regulatory partner controls the time and location of CDK activation. The process of
cylin-CDK assembly is also controlled although this process is less well understood.
b. Posttranslational modification: In addition to association with cyclins, maximal
activation of CDKs may require phosphorylation of its activation loop (T-loop) by CDKactivated kinases (CAKs), (i.e. Thr-160/161 in CDK1); the unphosphorylated complex is
typically 200-fold less active. CDK5 is a remarkable exception and does not require
phosphorylation for activation. Other kinases are able to mediate T-loop CDK
inactivation; for example, phosphorylation of Thr17 or Tyr15 by the wee/myt 1 kinases
inhibits CDK1 activity. CDK9 which has high homology with CDK5 may not require
phosphorylation for activation either.
c. Low molecular weight protein inhibitors/activators: cells, bacteria and virus also express
low molecular weight proteins - the p21 gene family (p21, p27, p57) and the p16 gene
family (p15, p16, p18, p19) - natural inhibitors or activators of CDKs.

1.3.1.3 CDK5
CDK5 is a unique member of CDK families
CDK5 was discovered in the early 1990s by biochemical purification from bovine brain and its
function was determined by virtue of its close sequence homology to human CDK1.38, 39 It has a
60% sequence homology with CDK1 and CDK2, yet a role for CDK5 in cell-cycle regulation
has not been identified.
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CDK5 is a proline-directed knase that phosphorylates serines and threonines immediately
upstream of a proline residue. In addition to an absolute requirement for proline in the +1
position, CDK5 shows a marked preference for a basic residue in the +3 position and
phosphorylates the consensus sequence (S/T)PX(K/H/R), where S or T are the substrate serine or
threonine, X is any amino acid, and P is the proline in the +1 position.40 CDK1 and CDK2 have
an identical substrate preference to that described above for CDK5.
Like other CDKs, CDK5 needs association with a binding partner for activation, but this protein
is not exclusively a cyclin protein. Two activators of CDK5, p35 and p39, have been identified.
Although there has little sequence homology with cyclins, molecular modeling and the crystal
structure of p25 and CDK5 complex (p25 is a truncated form of p35) suggest that p35, p39, and
cylins may present similar tertiary structures.41 The spatial and temporal expression of p35 and
p39 regulate CDK5 activity. P35 and p39 are expressed highest in stable neurons in the nervous
system.42 They both are likely to be membrane associated proteins as they have and aminoterminal myristoylation signal motifs.43 P35 is an unstable protein with half life of 20-30
minutes44; this is consistent with the postulate of p35 as a sequestered signaling protein released
as cellular demands require.
Unlike other CDKs, CDK5 does not require phosphorylation of the equivalent Ser 159 in the
activation loop for activation. The crystal structure of CDK5/p25 showed that the interaction
with the regulatory p25 subunit is sufficient to stretch the activation loop of CDK5 into a fully
active conformation and remove the autoinhibitory PSSALRE helix45.
Physiological function of CDK5
CDK5 regulates a variety of processes in neurons.46, 47 It plays a central role in neuronal
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migration during central nervous system (CNS) development.47 Mice deficient in Cdk5 or
double deficient in p35 and p39 exhibit severe defects in the layering of the cerebral cortex.48-50
CDK5 regulates the actin and microtubule cytoskeletons and modulates cell adhesion, neurite
outgrowth, and cell motility.46 Many synaptic proteins have been shown to be CDK5 substrates,
suggesting that CDK5 is involved in various aspects of synaptic function, including
dopaminergic signaling, neurotransmitter release, and membrane cycling.51, 52 Thus the
development of a knock out mode of CDK5 is not likely. No knock-down model for CDK5 has
yet been reported.
Deregulation of CDK5 and neurodegeneration
The calcium-dependent thiol protease, calpain, can be activated by elevated cellular levels of
calcium, and cleaves p35 or p39 to the freely soluble proteolytic segments p25 and p29
respectively (Figure 11).53
P25 contains all the elements necessary for CDK5 binding, and can efficiently activate CDK5 in
vitro and in vivo. However, p25 differs from p35 in stability and distribution.55 P25 has a half
life 5 – 10 fold longer than p35. P25 is 208 residue C-terminal proteolytic product of p35.
Lacking the N-terminal myristoylation signal motif, p25 is unlikely to be membrane bound and
as a result is free to distribute through out the cell body and nucleus. Therefore, p25 may cause
prolonged activation and mislocalization of CDK5.
The CDK5/p25 complex has been found to contribute to neurodegeneration by
hyperphosphorylation of tau proteins.55 Tau is the major microtubule-associated protein in
neurons and stabilizes microtubules. CDK5/p25 phosphorylates tau at a number of proline-
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directed serine/threonine sites, resulting in tau dissociation from and destabilization of
microtubules. Hyperphosphorylated tau dissociates from microtubules and forms paired helical
filaments (PHFs) that aggrate to deposit as neurofibrillary tangles (NFTs) (Figure 12).56 NFTs
are hallmarks of several neurodegenerative diseases including Alzheimer’s Disease. Calpain
activation, p25 accumulation, CDK5 colocalization with NFTs and CDK5 activity elevation have
all been observed in AD brain specimines.57-59

Figure 11. Cleavage of p35 to p25.54

Although there are other kinases including glycogen synthase kinase 3β (GSK3β) and
extracellular signal-regulated kinase 2 (ERK2) that can hyperphosphorylate tau56, only CDK5
can produce, by itself, the pattern of tau hyperphosphorylation (ser202-P or thr205-P) found on
tau in AD.60 CDK5 can also effect a priming phosphorylation of tau (at ser202 or thr205)
facilitating subsequent phosphorylation by GSK3β.61, 62 Immunohistochemical staining
identifies co-localization of CDK5/p25 with pre-tangle neurons and suggests that CDK5
precipitated NFT formation is an early event in AD progression.63 Therefore, it is postulated that
selective inhibition of the CDK5/p25 complex may be a useful component for AD therapy.
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Figure 12. Intracellular neuronal aggregates in tauopathies.56

CDK5 structure
Several crystal structures of CDK5/p25 with different inhibitors have been reported.64, 65 Like
other CDKs, it has N and C terminal lobes with the ATP binding catalytic cleft in between. The
N-terminal domain contains mostly β-sheets and the C-terminal domain α-helices. The
PSTAIRE helix behaves as a hinge between two rigid β-sheet “clam shell” regions in the ATP
binding site.
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Figure 13. Ribbon diagram of the CDK5/p25 complex.65 CDK5 is shown in gray, p25 in blue. The
ATP‐binding pocket between the N and C terminal lobes of the kinase is occupied by (R)‐roscovitine
(yellow). The main structural elements of the kinase have been labeled.

1.3.2 Prior medicinal chemistry (categories of inhibitors)
1.3.2.1

Kinase inhibitors

One of the important catalysts for the discovery of kinase inhibitors is the availability of the
three-dimensional structures of kinases and their complex with ATP or inhibitors. All kinase
structures determined to date exhibit a highly conserved catalytic domain consisting of the N27

and C-terminal lobes connected by a hinge region. Mg-ATP situates in a deep cleft between the
two lobes.
Directly adjacent to the ATP binding pocket, there is a pocket, namely the interior pocket,
created by the activation loop which includes the conserved DFG motif (Figure 14 b,d).66 In the
“DFG out” comformation, the phenylalanine residue of the DFG motif moves more than 10 Å
from its position in the ATP-bound active kinase active conformation. Ejection of the generated
ADP produces a pocket where the phenylalanine used to reside. Based on various binding sites
on the surface of the kinases, kinase inhibitors fall into three major classes, namely type I, II, and
III.
Type I kinase inhibitors bind in the ATP binding pocket and do not require the DFG motif to
adopt a “DFG-out” conformation for binding. Type I inhibitors typically form 1 to 3 hydrogen
bonds with the kinase hinge residues; these hydrogen bonds mimic those normally formed by the
exocyclic amino group of adenine (Figure 14 a,c).66 The region occupied by type I inhibitors
can be further divided into subregions: hydrophobic regions I and II, the adenine region, the
ribose region and the phosphate-binding region (Figure 14 a). Although the adenine region is
invariably occupied by all type I inhibitors, the ability of type I inhibitors to present diverse
functionality to other regions can and has formed the basis for inhibitor selectivity among
different kinases.
Type II kinase inhibitors occupy both the ATP binding pocket and the interior pocket. Because
the amino acids surrounding the interior pocket are less conserved relative to those in the ATP
binding pocket, it has been proposed that it may be easier to achieve kinase selectivity with type
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Figure 14. Binding modes of kinase inhibitors.66 a. Interactions between a type I inhibitor and the kinase.
b. Interactions between a type II inhibitor and the kinase. c. ATP binding site with a DFG‐in activation‐
loop conformation (active conformation). d. A type II inhibitor binding to the kinase in the DFG‐out
conformation (inactive conformation).

II inhibitors. Type II inhibitors typically have potent cellular activity, presumably because they
recognize (or induce) the DFG-out conformation, which has a lower affinity for ATP than for the
active kinase. The known crystal structures of type II inhibitors and the kinases reveal that they
all possess a conserved hydrogen-bond donor-acceptor pair between the ligand and the residues
in the interior pocket: one hydrogen bond with the side chain of a conserved Glu in the αC-helix
and the other with the backbone amide of Asp in the DFG motif. All type II inhibitors also have
a hydrophobic moiety that is located immediately after the hydrogen bond donor-acceptor pair
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and that forms van der Waals interactions with the interior pocket. Type II inhibitors can also
extend into the adenine region and form one or two hydrogen bonds with kinase hinge residues.
Type II inhibitors are not applicable to all kinases. There is a key residue serving as gatekeeper
to the interior pocket and controls steric accessibility to inhibitors. In kinases with a bulky gatekeeper residue, inhibitors cannot access this interior pocket from the ATP- binding pocket.
Type III inhibitors generally refer to inhibitors that bind to non-catalytic allosteric sites, alter the
global kianse comformation, and prevent substrate binding.32 These inhibitors may allow greater
specificity in protein kinase inhibition with fewer off-target side effects.

1.3.2.2 CDK inhibitors
Most known CDK inhibitors are type I kinase inhibitors. CDK2 structure is the most exploited
CDK target due to its early recognition as a cell-cycle check point. Its gate keeper residue is
Phe-80, and the interior pocket is not accessible, thus the type II inhibitors are not applicable
here.67, 68
Despite striking chemical diversity, all ATP-competitive CDK inhibitors share some common
properties35: 1) they have low molecular weights (<600); 2) they contain a flat, hydrophobic
heterocycle; 3) they bind mostly by hydrophobic interaction and mimic the hydrogen bond
pattern of the expected adenine substrate with the kinase.
Based on their chemical structures, they fall into the following categories37, 69, 70:
Purines
Substituted purine inhibitors are based on the heterocyclic structural core present in ATP itself
(Figure 15). The initial purine analogs exemplified by olomoucine 4 showed good potency for
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CDK1, CDK2, and CDK5 but were not active for CDK4 and 6. Close analogs with
modifications of substituents at N9 and C2 position improved potency and selectivity (roscovitine
5 and bohemine 6). The 6-benzylamino substituent can be replaced with 6-anilino groups to
yield the purvalanol series. In these purine inhibitors, the 6-amino and N7 nitrogen interacts with
the hinge region in the ATP binding pocket as an H-bond donor and an H-bond acceptor acceptor
and donor.

Figure 15. Purine CDK inhibitors.

respectively. Other series were also discovered with variations at the 2, 6, and 9 positions. 9-13
are conformationally constrained analogs. 14 and 15 have an oxygen at the 6 position instead of
the NH group, thus this series has a flipped binding mode, with N3 and N9 acting as the H-bond
Pyrimidines
Phenylaminopyrimidine is a common scaffold of kinase inhibitors. Some CDK-selective
analogues from this class have been identified. i.e. 16 and 17 are CDK1/2 and CDK4 selevtive
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inhibitors respectively. 18 was designed based on the purine inhibitor 14. The
aminothiazolopyrimidine analogue 19 is a subnanomolar inhibitor of CDK2. (Figure 16)

Figure 16. Pyrimidine CDK inhibitors.

Oxindoles

Figure 17. Oxindole CDK inhibitors.

Oxindoles (i.e. indirubin) are naturally occurring or synthetic compounds that have been used in
traditional Chinese medicine for the treatment of chronic diseases such as leukemia. Many
oxindole- inhibitors were developed, largely as CDK2 inhibitors. Examples are shown in Figure
17.
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Various heterocyclic templates
These include pyrido[2,3-d]pyrimidines such as 25, pyrazolo[3,4-b]pyridines such as 26, 4anilinoquinazolines such as 27, aminothiazoles such as 28. (Figure 18)

Figure 18. Other heterocyclic templates.

Flavonoids
This classe is represented by flavopiridol 29 (Figure 19), which is a naturally occurring alkaloid
showing cytotoxic properties against tumor cell lines. It is the first CDK inhibitor to enter
clinical trials. Flavopyiridol has recently been co-crystallized with CDK9 and the basic nitrogen
resides in the Mg2+ site associated with ATP71.

Figure 19. Flavonoids and Stauosporine derivatives.
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Stauosporine derivatives
Staurosporine 30, a metabolite from Streptomyces sp, is a natural and broad specificity ATPcompletive kinase inhibitor. Some of the stauosporine derivatives (Figure 19) show excellent
antitumor activities, and come effects may be due to CDK inhibition. Staurosporine is notably
non-selective in its inhibition of kinases72.
Others
New scaffolds for compounds are continuously discovered to display CDK inhibitory activity,
incluing diarylureas, butyrolactones and paullenones.
Of the various structures types of CDK inhibitors, some are not selective for any specific CDKs
(i.e. flavopiridol, oxindole 16), some inhibit CDKs 1, 2, 5 (and possibly CDK9) (i.e. olomoucine,
(R)-roscovitine, indirubin-3’-monoxime), and some are selective for CDKs 4 and 6 (i.e. CINK4).
No inhibitor that is selective for a single CDK has been discovered. This is probably due to the
highly conserved amino acids lining the CDK ATP-binding pocket.35

1.3.2.3 CDK5 inhibitors
As previously described, no specific CDK5 inhibitor has yet been discovered. Several kinase

Figure 20. Structure of (R)-roscovitine, aloisine-A, and indirubin-3’-oxime.
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inhibitors were also found to have CDK5 inhibitory activity. Three of them, indirubin-3’-oxime,
(R)-roscovitine, and aloisine-A, are of particular interest (Figure 20 and Table 2), because their
cocrystal structure with CDK5/p25 are known, thus their interactions with the enzyme are well
charcterized.45
Table 2. Selected CDK inhibitors.73‐75
Inhibitor

CDK1/Cyclin B
(μM)

CDK2/Cyclin A, E
(μM)

CDK5/P25
(μM)

CDK4/Cyclin D
(μM)

R‐roscovitine

0.45

0.7

0.16

>100

Aloisine‐A

0.15

0.12

0.2

‐

Indirubin‐3’‐
oxime

0.08

‐

0.1

‐

(R)-Roscotivitine is a purine based CDK inhibitor selective for CDKs 1, 2, 5, 7, and 9. It also
interacts with several other targets, although with a lower affinity (DYRK1A, CK1, pyridoxal
kinase).72, 76-78 It is slightly more potent at CDK5 than CDK2. It is also much more selective
over GSK3β (> 1000 fold), which is another important kinase involved in tau
hyperphosphorylation.56 The (S)-isomer is 10 fold less potent. (R)-roscotivitine is currently in
phase III clinical trials against non-small cell lung cancer, in phase II against nasopharyngeal
cancer, in phase I against various renal disease, and in preclinical evaluation against polycystic
kidney disease, Alzheimer’s disease, stroke, and inflammation. Side effects are primarily
limited to GI irritation.
Indirubin-3’-oxime belongs to the oxindole class. It is not selective for CDK5, CDK2 and it is a
potent inhibitor of GSK3β (IC50 = 0.022 μM).
Aloisine-A is the most potent compound of aloisines, which contains the 6-phenyl-[5H]-
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pyrrolo[2,3-b]pyrazine scaffold and are selective inhibitors of CDK1, CDK2, CDK5 and GSK3.
A high through-put screen by Ahn, J. S. et al. was conducted to search for CDK5 inhibitors, and
three inhibitors with different mechanisms of action were identified (Figure 21).64 Compound
33 binds competitively with ATP in the ATP pocket; compound 34 is also a competitive
inhibitor for ATP but a non-competitive inhibitor for tau; compound 35 does not compete with
ATP and does compete with tau at low concentrations of tau.
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Figure 21. Structure of compound 33‐35.

As indirubin-3’-oxime, (R)-roscovitine and aloisine-A, compound 33 and 34 all bind to the ATP
pocket, they were aligned to define the chemical space within the CDK5 ATP pocket.64 Figure
22a shows that all five inhibitors have important hydrogen bonding with the hinge region
residue. Four of them interacted with the N-H group of Cys83, three with the carbonyl group of
Glu81, and four with the carbonyl group of Cys83. Figure 22 b shows that in one dimension,
they all share a flat plane, with important hydrophobic interactions with the enzyme on two sides
of the plane, while polar interactions are made along the flat dimension of the inhibitors.
Because CDK5 dysregulation has emerged as an attractive target for the treatment of CNS
disorders, efforts toward developing specific CDK5 inhibitors have recently appeared.
A group from Pharmacia identified a CDK5 inhibitor 36 containing the thiozole urea structure
36

via high throughput screen (HTS). This scaffold has been explored previously as a CDK2
inhibitor scaffold. Of particular interest is that this compound exhibits a modest degree of
specificity for CDK5/p25 versus CDK2/cyclin A. Modification yielded compound 37 with
greatly improved selectivity over CDK2 (Figure 23).79

64

Figure 22. Aligned overlay of CDK5 and five inhibitors. Blue: 33; red: 34; green: aloisine‐A; orange:
indirubin‐3’‐oxime; yellow: (R)‐roscovitine. a. Atoms involved in forming H‐bonds between the ligand
and the hinge region residues of CDK5 are shown in spheres. b. The CDK5‐aligned residues shown are
“critical contact residues,” defined by having their solvent‐accessible surface area change by at least 10
Å2 upon binding to each of the five inhibitors. The circled regions A, B, and C denote the general
locations of atoms involved in forming H‐bonds with Cys83 H, Cys83 O, and Glu81 O, respectively.

CDK5 IC50 = 1 μM
CDK2 IC50 = 10 μM

CDK5 IC50 = 0.9 μM
CDK2 IC50 > 100 μM

Figure 23 CDK5 inhibitors from Pharmacia.
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Starting from the HTS hit 38, the Pfizer group also developed thiozole urea inhibitors.80
Modifications to 38 successfully decreased the CDK5 IC50 to < 10nM and improved CDK2
selectivity to > 10-fold, exemplified by 39 (Figure 24).

CDK5 IC50 = 321 ± 18 nM
CDK2 IC50 = 318 ± 18 nM

CDK5 IC50 = 8 ± 1 nM
CDK2 IC50 = 96 ± 12 nM

Figure 24. CDK5 inhibitors from Pfizer.

The Amgen group also discovered the HTS hit 40 containing thiozole urea moiety (Figure 25).
Based on the co-crystal structure of CDK2 and 40, an active site homology model of CDK5 was
deveploped for further exploration and optimization of potent CDK5 inhibitors. They proposed
there is an intramolecular hydrogen bond between N1 and N3-hydrogen, which was believed to
help pre-organize the inhibitor to a U-shaped binding conformation, and designed the ring
constrained analogs 3,4-dihydro-1H-quinazolin-2-one 41 and quinolin-2(1H)-one 42.81, 82

CDK5 IC50 = 15 nM
CDK2 IC50 = 4.6 nM

Figure 25. CDK5 inhibitors from Amgen.
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Chapter 2
Chemical Literature Review
2.1 Tubulysin
Although at first sight the synthesis of tubulysins might not appear to be extremely challenging,
to date there is only one published total synthese of tubulysin D, which suggests that several
important challenges must be surmounted. Indeed, a number of challenging synthetic issues
have been described in the review by Dömling and Richter20, who reported that the major hurdles
are: 1) the installation of the acid and base labile N,O-acetal ester, 2) the synthesis of the
configurationally and chemically sensitive thiazole fragment, and 3) the assembly of the peptide
framework, as a consequence of the steric congestion of the central Tuv region.
Although the last point is challenging, the common strategy used in tubulysin synthesis is to scan
known peptide coupling reagents or to use acyl halide instead of the carboxylic acid. This
review will be focusing on synthesis of the two unusual amino acid fragment Tub and Tup.
The Höfle synthesis
Höfle claimed a total synthesis of tubulysins in patent.83
The synthesis of Tuv fragment (Scheme 1) started from L-valinol, which was converted to an
aldehyde and coupled by the Wittig reaction. The chemically labile N,O-acetal was installed in
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the last step. Cbz group was used to protect the amine because it can be cleaved under catalytic
hydrogenation which does not affect the exquisitely sensitive N,O-acetal. The reduction of the
ketone and acelation in Tuv was done after assembly of the tetrapeptide.

Scheme 1. Synthesis of Tuv fragment by Höfle et al.

For the Tup fragment (Scheme 2), again, the γ-amino ester 50 was synthesized from the α-amino
alcohol 47 by Swern oxidation and Wittig reaction. Evan’s oxazolidinone chemistry was used to
install the methyl group with the right stereochemistry.

Scheme 2. Synthesis of Tup fragment by Höfle et al.

The Dölming synthesis
The Morphochem group led by Dömling has claimed a total synthesis of tubulysins in patent84
and published17, 85 the total synthesis of tubulysin U and V.
The Morphochem approach to tubulysins is based on a novel multicomponent reaction that
allows a versatile combinatorial approach to the Tuv 2-acyloxymethylthiazole 55 (Scheme 3).
Thus, aldehyde 51, thioacetic acid 52, and 3-(N,N-dimethylamino)-2-isocyanoacrylate 53 in the
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presence of a Lewis acid afforded the complex target thiazolyl framework 54 smoothly, albeit in
rather low yields. The stereochemistry of the hydroxyl (tubulysin V) or acetate (tubulysin U) in
Tuv fragment was achieved by converting the acetate to ketone and reduction on the tripeptide
Ile-Tuv-Tup tripeptide.

N

O
PG

CHO

N
H

+
SH

OAc
N
H

MeO2C

OAc

O
N

PG
OMe

O
N

N

S
54

(-HNMe2)

CN
53

52

51

PG

+

S

O
O

OMe

R1

55

Scheme 3. Multicomponent synthesis (Morphochem) of the Tuv fragment. PG=protecting group.

Similar to Höfle, the patented synthesis of the Tup fragment 56 started from L-phenylalaninol,
and the stereochemistry of the methyl group was controlled by Evans’ oxazolidinone (Scheme
4).

Scheme 4. Retro synthesis of Tup fragment by Morphochem in patent.

For the published method of Tup synthesis, aziridine 60 was used as the electrophile instead of
triflate 57 (Scheme 5). However later they found it gave the epi-Tup.
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Scheme 5. Retro synthesis of Tup fragment by Morphochem published. EWG = electron‐withdrawing
group, Aux = chiral auxiliary.

The Wipf synthesis
Wifp’s synthesis of the γ-amino ester 62 in Tuv and 70 in Tup was similar to that of Höfle. In
their initial Tuv synthesis86 (Scheme 6), α-hydroxylation to 62 was carried out by the Davis
reagent and the protected α-silyloxy ester was then transformed into thioamide 64, which was
submitted to condensation with bromopyruvate to form thiozole 65. The Cbz group was used
because it was supposed to be cleaved under neutral conditions. However, they failed to remove
the Cbz group on Tuv-Tup dipeptide.

Scheme 6. Wifp’s initial synthesis of Tuv fragment.

In their second synthesis (Scheme 7)87, their stated goal was to make N14-methyl analog instead
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of N,O-acetal, thus Cbz was replaced by Boc. The synthetic stragegy was also changed. After
one carbon homologation of L-valine, the Cbz-β-amino ester was converted to N-methyl-Boc- βamino aldehyde 67 by several steps. The syn-alcohol 68b was constructed by the addition of the
thiazole anion to aldehyde 67. The anti-alcohol 68a was also used to make the epimer ananlog.
(See 1.2.2.4)

Scheme 7. Wifp’s second synthesis of Tuv fragment.

In Tup synthesis86, a fairly stereocontrolled hydrogenation of the α,β-unsaturated ester yielded

Scheme 8. Wifp’s synthesis of Tup fragment.

the two diastereomers of esters, which were converted to alcohols and separated (Scheme 8).
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The Ellman synthesis
In Ellman’s total synthesis of tubulysin D88, chiral sulfinamides are used for the rapid and
stereo- controlled assembly of Tup and Tuv. The labile and unusual N,O-acetal was introduced
by selective N-alkylation in the presence of an N3-masked isoleucine, which was subsequently
transformed into the amine under neutral conditions to prevent cleavage of the labile acetal.
They used of a mild and specific reagent (Me3SnOH) for the methyl ester cleavage to give 80 in
a highly selective manner (Scheme 9).

Scheme 9. Ellman synthesis of Tubulysin D.88, 89

This total synthetic route allowed Ellman’s group to make several analogs of tubulysin D with
modifications on different parts of the molecule.27
After the discovery that the N,O-acetal was not required for activity, they made a more expedient
synthesis of N14-methyl analogues90, which is not limited to neutral conditions. The ester of Tuv
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could be easily hydrolyzed under acidic conditions, so the methyl ester of aldehyde 77 was
replaced by ethyl ester, which was more synthetically accessible. 1,3-Tetrahydrooxazine
stragety was employed to protect the Tuv alcohol. Thus alcohol deprotection and cleavage of the
N-sulfinyl group were carried out simutaneouly (Scheme 10).

90

Scheme 10. 1,3‐Tetrahydrooxazine stragety for protection of 1,3‐alcohol in Tup.

The Fecik Synthesis
Fecik’s synthesis of Tuv fragment is very similar to Wipf’s second synthesis of Tuv.29 The
major difference is that a Weinreb amides was used instead of an aldehyde, thus the product is a
ketone (Scheme 11), which could be reduced stereoselectively by CBS reagent after assembly of
the Ile-Tuv-Tup tripeptide.18

Scheme 11. The key step in Fecik’s synthesis of Tuv fragment.

Scheme 12. The key step in Fecik’s synthesis of Tup fragment.
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For Tup synthesis, diastereoselective alkylation of the actam 86 was employed (Scheme 12).29
This method was used to synthesize the gem dimethyl, demethyl and epimeric Tup analogs.
Other synthesis
Friestad’s group developed a method of stereoselective Mn-mediated radical Mannich coupling
of functionalized iodides and hydrazones to provide α-substituted γ-amino acid building blocks.
This method was used in both Tuv and Tup fragment synthesis.91 No further publications from
this or other groups expanded or employed this strategy.
Zanda’s group developed the total synthesis of tubulysin U and V, which can provide hundreds
of miligram quantity of tubulysin U and V.19

2.2

Benzimidazoles92

2.2.1 Core structure
Physical properties of benzimidazole

Figure 26. Structure of 1H‐Benzimidazole.

1H-Benzimidazole is a planar, bicyclic molecule with a benzene ring fused at the 4- and 5positions of imidazole. The compound is numbered as shown in Figure 26.
In general, benzimidazoles are high melting solids (1H-benzimidazole mp= 170 oC, 1-methyl -1-
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H-benzimidazole mp =660 oC). Those molecules that have a free NH proton are associated
through intermolecular hydrogen bonding, which is no longer possible when that proton is
replaced by an alkyl group. The melting and boiling points are therefore lower in the Nsubstituted derivatives. Benzimidazoles are much less soluble in water than imdazoles.
Benzimidazoles have high thermal stability, high aromatic stability, and are resistant to acids,
bases, heat, oxidation and reduction.
The annular NH proton exchange is so fast that only one species is observable on the NMR
timescale at ordinary temperatures; 4(7)- and 5(6)- substituted benzimidazoles appear to be a
single compound rather than a tautomeric mixture until the NH proton is replaced by an alkyl or
other group.
Table 3. Basic pKa values of benzimidazoles.94‐96

Substituent

Basic pKa in H2O

Substituent

Basic pKa in 50% aq EtOH

H

5.53

H

4.98

1‐Me

5.57

1‐Me

4.88

2‐Me

6.19

2‐NH2

3.37

4‐Me

5.67

5‐Cl

3.92

5‐Me

5.81

5‐OMe

5.07

2‐Et

6.19

4‐OMe

4.98

5‐NH2

6.11

2‐Ph

4.51

5‐OH, 1‐M3

5.94

4‐NO2

3.33

1‐oxide

2.90

5‐NO2

2.67

Benzimidazole is amphoteric, forming salts with both acids and bases, but the fused benzene ring
decreases the basicity of the imidazole, and electron withdrawing groups can accentuate this
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trend93. Unless there is considerable electron withdrawal by substituents, benzimidazoles are
able to form well-defined salts with acids such hydrochloric acid. Some basic pKa values of
benzimidazoles are listed in Table 3.

2.2.2 Benzimidazole synthesis overview92
Benzimidazoles can be synthesized by ring-closure reactions (cyclization), ring transformation,
aromatization and substituent modification of a preformed benzimidazole.
Ring-closure reactions
This is the most common method to synthesis benzimidazoles, and formation of 1-2 and 2-3 C-N
bonds is the most versatile mehod. It involved reaction between a suitably substituted 1,2diaminoarene (or under reducing conditions a 2-nitroaniline) and a carbonyl species, exemplified
by Scheme 13. The latter can be a derivative of carbonic acid, a carboxylic aid or derivative,
and aldehyde or ketone, or, under oxidizing conditions, and alcohol. The carbonyl species
control the nature of the eventual 2-substituent, which can be alkyl, aryl, amino, oxy, sulfanyl, or
hydroxy. Substituents in the 1,2-diaminoarene reactant become 1-,4-, 5-,6- and 7- substituents
on benzimidazole.

Scheme 13. Formation of 1‐2 and 2‐3 bonds in benzimidazoles.

Ring-closure reaction with formation of one N-C bond is also a common method of
benzimidazole synthesis. Reactions involve formation of 1-2 or 2-3 bonds are very similar to
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that form both the 1-2 and 2-3 bonds. The most common reaction type cyclizes a 1,2diaminoarene in which one of the amino groups has been acylated (Scheme 14).

Scheme 14. An example of formation of 1‐2 or 2‐3 bonds in benzimidazoles.

Synthesis by substituent modification
Electrophilic substitution occurs most readily in the benzene ring, commonly in the 5 (6)
position, but substituents already present on the ring can modify the next preferred position of
substitution. The substrates react much more readily if they are present as the anions, whether
deprotonated on nitrogen by a base, or as C-lithio compounds. However, this method is
generally less successful than the ring synthetic procedure.
The 2-position is the most common reaction site for nucleophilic aromatic substitutions,. For
example, benzimiazol-2-amine can be formed by treatment with sodium amide followed by
reduction.

2.2.3 Identification of desired SAR points and related synthesis review

Figure 27. Desired SAR points of benzimidazole based (R)‐roscovitine analogs.
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The desired SAR points of (R)-roscovitine analogs will be 1, 4, and 6 positions of the
benzimidazole (Figure 27). Here synthesis of 4,6- disubstituted benzimidazoles and 1substituted benzimidazoles are reviewed.

2.2.3.1 4,6- Disubstituted benzimidazoles
Sharma and coworkers97 reported the synthesis of 5,7-dibromo-1H-benzo[d]imidazole-2-thiol, 97
and related compounds (Scheme 15). 96 was reduced by Raney nickel and hydrazine hydrate
and treated carbon disulfide subsequently to give 97 in 50% yield.

Scheme 15. Synthesis of 5,7‐disubstitued 1H‐benzo[d]imidazole‐2‐thiol.

Gillespie and colleagues reported the synthesis of 6-methoxy-4-nitro-1H-benzo[d]imidazole 99
by cyclization of the diamine 98 and conc. sulfuric acid and sodium nitrite (Scheme 16).

Scheme 16. Synthesis of 6‐methoxy‐4‐nitro‐1H‐benzo[d]imidazole.

Hoover and colleagues synthesized 4,6-dichloro-1H-benzo[d]imidazole 102.98 The diamine 100
was cyclized to benzimidazole 101 under Philips condition. Reduction of the nitro compound
102 followed by chlorination of the amino group gave the dichlorinated compound 103
(Scheme17).

50

Scheme 17. Synthesis of 4,6‐dichloro‐1H‐benzo[d]imidazole.

Knochel and coworkers reported a mild synthesis of 2,6-substituted benzimidazoles by the
reduction of functionalized nitroarenes with phenylmagnesium chloride (Scheme 18).99

Scheme 18. Synthesis of 6‐iodo‐N,N‐dimethyl‐4‐nitro‐1H‐benzo[d]imidazol‐2‐amine.

Iodination of 104 was carried out with silver sulfate and iodine in ethanol. Then 105 was treated
with 106 in toluene at 140oC to give 107. The resulting protected ortho nitro substituted aniline
107 was treated with phenylmagnesium chloride to give benzimidazole 108.

2.2.3.2 1-Substituted benzimidazoles
Holen and coworkers reported the synthesis of N-1-substituted 2-trichloromethylbenzimidazoles
(Scheme 19). N-Substituted diaminoarene 109 was dissolved in the protic solvent and then
methyl trichloroacetimidate 110 was added slowly dropwise to the resulting solution to give 111.
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Scheme 19. Synthesis of 1‐methyl‐2‐(trichloromethyl)‐1H‐benzo[d]imidazole.

Leonard and colleagues reported the synthesis of benzimidazoles using carboxylic acids and
ortho esters (Scheme 20). 112 was reduced to the N-substituted diaminoarene113 with Raney
Nickel in DMF and ammonia. After reduction, the imtermediate 113 was dissolved in triethyl
orthoformate and formic acid and refluxed for 3 hours to yield 114.

Scheme 20. Reaction of 2‐nitroanilines with carboxylic acids and ortho esters.

Suschitzky and coworkers reported another method for the synthesis of N-1 substituted
benzimidazoles (Scheme 21). Acylation of 115 with acetic anhydride gave acylated precursor
116. Then heating with phosphoric acid cyclized 116 to 1,2-disubstitued benzimidazole 117.

NH2

Ac2O, heat

NH

CH3
O

NMe2
115

PPA, heat

N
N

NMe2
116

117

Scheme 21. Benzimidazole formation from N1, N1‐disubstitued 1,2‐diaminoarenes.
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Chapter 3
Statement of the Problem
3.1 Tubulysin
Goal of the research:
To modify the structure of tubulysin D with the twin goals of retaining potency while reducing
metabolic liability.
Hypothesis:
The structure of tubulysin D can be modified to increase the chemical and biological stability
while retaining the anti-proliferative activity against tumor cells.

Figure 28. Possible modifications in Tuv fragment of tubulysin.
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Specific goals:
1. To provide adequate amounts of the Tuv-Tup portions to prepare N-analogs that replaces
the acyl aminal.
2. To develop a synthesis pathway that allows point variation of the isopropyl of the Tuv

fragment (Figure 28).

3.2 CDK5
Goal of the research:
To develop novel potent and selective inhibitors of CDK5 to analyze the role of CDK5 in
pathology of Alzheimer’s disease.
Specific goals: To synthesis the two serious of compounds:
1. Target compounds of the 6-benzylbenzimidazole series:

Figure 29. Target compounds of the 6‐benzylbenzimidazole series.

Rationale:
Based on the crystal structure of (R)-Roscovitin-CDK5/p25 complex (Figure 29), it was
concluded that the most significant bonding pattern is from the purine N7 (H-bond acceptor) and
the exocylic NH at C6 of roscovitine (H-bond donor) to the amide NH and the acyl of Cys83,
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respectively. However, purine N1, N3 and the exocylic NH at C2 are not within hydrogen
bonding distance of any polar functionality. In addition, the floor of the purine binding region is
derived from Leu133 and the top of the purine binding region is derived from Ile10. This

c

d

Figure 30. Structural analysis of (R)‐roscovitine‐CDK5/p25 (PDB ID: 1UNL). a. structure of (R)‐roscovitine
b. Crystal structure of (R)‐roscovitine‐CDK5/p2545 c. 3‐dimentional analysis of (R)‐roscovitine‐CDK5/p25.
d. Ligplot® of (R)‐roscovitine‐CDK5/p25 interaction

suggests that replacement of purine with benzimidazole and the exocylic NH at C2 with CH2
(Figure 30) would not only retain the key H-bonding pattern but also add hydrophobic
interactions with Ile10 and Leu133. The latter replacement is also expected to increase
selectivity because the exocylic NH at C2 forms an important H-bond with Glu131 of CDK2100
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(Figure 31). Additionally, the floor of the ATP binding site of GSK3β has considerable polar
character compared to CDK5.
Thus the benzimidazole analogs were designed (Figure 31). From the SAR of purine CDK
inhibitors, the importance of the substitents at different positions is different: 2 > 6 > 9. Here the

Figure 31. Structural changes to (R)‐roscovitine.

Figure 32. Structure analysis of (R)‐roscovitine‐CDK2 (PDB ID: 2A4L). Model derived from 2A4L, modeled
in Moe. a. 3‐dimentional analysis of (R)‐roscovitine‐CDK2. b. H‐bonding pattern in (R)‐roscovitine‐CDK2.

9-position of the purine is the 6-postion of the benzimidazole. The polar and non-polar ribose
binding pocket could be further explored by attaching various R groups at the 6-position of the
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benzimidazole.
The initial modeling based on the a published scoring algorithm developed by the Madura
laboratory101 predicted compounds 120a,b to be the most potent compounds (see appendix).
2. Target compounds of the 6-aminobenzimidazole series:

Figure 33. Target compounds of 6‐aminobenzimidazole series.

Rationale:
Among the initial benzimidazole compounds synthezied in our lab, the only compound that
showed activity against CDK5 was rac-13, which had the most similar structure to (R)roscovitine but still 80 times less potent. Thus for new series of compounds, fewer changes of
the structure of (R)-roscovitine were planned. Only one or two nitrogens of the purine system
were replaced with carbons at a time. Because benzimidazole scalfold as inhibitors of CDKs
were reported120, the benzimidazole core was maintained and the NH linker was put back to the
6-position. Because the hydroxyl group was important for activity (rac-119 vs rac-122), it was
desired in the target compounds.
Additionally, the principle components scoring protocol of Madura may overestimate
hydrophobic interactions. As the scoring algorithm was apprently not suitable for this type of
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Table 4. Biological activity of the initial series of benzimidazoles synthesizeda.

Compound

IC50 (µM)

R
CDK1

CDK5

GSK3b

CK1

DyrK1A

CDK2A

Erk2

120a

‐

‐

‐

‐

‐

‐

‐

120b

‐

‐

‐

‐

‐

‐

‐

121a

‐

‐

‐

‐

‐

‐

‐

121b

‐

‐

‐

‐

‐

‐

‐

b

rac‐119

13

13

‐

‐

30

10

‐

b

rac‐122

‐

‐

‐

‐

‐

‐

‐

0.45

0.16

130

2.3

‐

0.7

14

5

(R)‐roscovitine

a.Biological data was kindly provided by Dr. Laurent Meijer (see appendix).. b Compound rac119 and 122 were designed by Dr. Patrick Flaherty and synthesized by Ishveen Chorpra. c. “-“
means inactive.
enzyme and inhibitor class, re-analysis with the Lig-X protocol and rescoring with the London
dG (see appendix) protocol was conducted. Compounds with the 6-side chain similar to
roscovitine scored much higher than the 6-benzyl analogs. Significantly, the 6-benzyl
compounds gave less active scores (see appendix). The new protocol and scoring method
predicted that the target compounds had favorable scoring and reasonable interactions with the
enzyme (see appendix).
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Chapter 4
Chemical Discussion
4.1 Tubulysin
The overall strategy of tubulysin synthesis was to synthesize the Tuv and Tup amino acids with
proper protection separately, and assemble the tetrapeptide by peptide coupling reagents
(Scheme 22).
The Tuv fragment could be disconnected between the β-homovaline moiety and thiozole
carboxylic acid moiety. To achieve modification of the isopropyl group, Evans’ asymmetric
oxazolidinone chemistry102 was used to synthesize the Cbz- β-homovaline (Scheme 23). The
synthesis started with isovaleric acid 132, which was converted to isovaleryl chloride 133 and
coupled with Evans’ chiral oxazolidinone to form 134. The enolate of 134 was formed by
treatment with NaHMDS, and then it was alkylated with tert-butyl bromoacetate asymmetrically
to give 135 in 86% yield. The chiral auxiliary was hydrolyzed by lithium hydroxide and
hydrogen peroxide to yield the corresponding carboxylic acid 136. Thermal Curtius
rearrangement of 136 by diphenyl phosphoryl azide (DPPA) and benzyl alcohol should afford
137 in 80 – 95% yield102, but loss of material due to experimenter error during transfer resulted
in only 17% yield. Hydrolysis of the tert-butyl ester 137 with trifluoroacetic acid and dimethyl
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sulfide afforded the Cbz- β-homovaline 138, which was smoothly converted to the Weinreb
amide 139. Thiazole-4-carboxylic acidcould be protected as the silyl ester in situ, and generate

Scheme 22. Overall strategy of tubulysin synthesis. LG = leaving group; P = protecting group.

the anion at 2-position by treatment with LDA, which could attack the Weinreb amide 139 to
afford the ketone 140.
There were two chiral centers in the Tup fragment. One could be from phenylalanine, and the
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other could be introduced by the first chiral center. This synthesis (Scheme 24) is very similar to
the Wipf’s synthesis.86 It started with L-phenylalanine 142, which was reduced to the
O

O

Cl
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O
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O

O

, DMF
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nBuLi, THF,
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O
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O
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O
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H

S

O
OH
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Scheme 23. Synthesis of Tuv fragment.

corresponding amino alcohol by sodium borohydride and iodine, followed by Boc protection to
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give 47. The alcohol 47 was converted to aldehyde 143 by Tempo oxidation, which was used
directly in the Wittig reaction give the α,β-unsaturated ester 70 in 55% yield. According to
Wipf, hydrogenation of 145 affords the two diastereomers 146a,b in 3:1 ratio, but they cannot be
separated by silica gel column chromatography.86 α,β-Unsaturated ester with similar structure to
70 have been reported to undergo catalytic hydrogenation followed by recrystallization to yield a
single diastereomer.103, 104 Recystallization was employed to give 146a as a single diastereomer
in 55% yield. X-ray crystal structure of 146a demonstrated it was the desired diastereomer (see
appendix).

Scheme 24. Synthesis of Tup fragment.

DIBAL-H reduction of 147 also afforded 143 in similar yield and purity (Scheme 25), but the
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Tempo oxidation procedure was more amenable to larger scale.

Scheme 25. Synthesis of compound 143 by DIBAL‐H reduction.

The formation of 70 was first carried out with a Horner-Wadsworth-Emmons reaction strategy
(Scheme 26). When DIPEA or DBU or LDA was used as the base, very low yield of 70 was
obtained, and the cyclized product 149 of the Z-alkene was also obtained. The selectivity for Ealkene formation could be improved by using other phosphonate, but Wittig reaction of the
stable ylide with the aldehyde 143 should form the E-alkene preferentially. So a Wittig reaction
strategy was used finally. 149 formed previously could be used to synthesize another
diastereomer of Tup, in future Tup SAR exploration.

Scheme 26. Synthesis of compound 70 with Horner‐Wadsworth‐Emmons strategy.

4.2 CDK5
N1-Substitution
Initially, our lab synthesized benzimidazole 99 with very good yield (Scheme 27). It was also
found that the 5-methoxy-3-nitrobenzene-1,2-diamine 98 could be selectively alkylated at N1
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position by reductive alkylation (Scheme 28). The intermediate 1-

Scheme 27. Synthesis of 5‐methoxy‐7‐nitro‐1H‐benzo[d]imidazole.

isopropylamine 151 was refluxed with formic acid and conc. HCl to form the 1-isopropyl
benzimidazole 152a. The crystal structure of 152a confirmed that desired regioisomer was
isolated.105 However, the isolated yield was very low, the procedure was problematic and
NaBH(HCOO)3 was unstable at room temperature, need to be freshly prepared, requiring in situ
preparation.

Scheme 28. Initial synthsis of compound 152a in our lab.

Thus direct N1-alkylation was tried on the preformed benzimidazole 99. It could be deprotonated
easily by potassium hydroxide powder, and then successfully benzylated at N1 position by benzyl
bromide. Although both two regioisomers were formed, they could easily be separated by
column chromatography. However when isopropyl iodide was used as the electrophile, a very
low yield of 152a was obtained, and the two isomers were very hard to separate with column
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chromatography. This may be due to the bulkiness of the isopropyl group which hindered the
nucleophilic attack, or to β-elimination of the iodide under basic conditions (Scheme 29).

Scheme 29. Dirrect N1‐alkylation of preformed benzimidazole 99.

Alternatively, alkylation then cyclization method was used (Scheme 30). Commercially
available and more stable NaBH(AcO)3 was used instead of NaBH(HCOO)3, the ratio of conc.
HCl to formic acid was increased, and catalytic amount of BHT was added to protect the
intermediate 151 from oxidation. These changes improved the isolated yield of 152a, as well as
establishing the procedure as more reliable and simple.

Scheme 30. Improved synthesis of 1‐isopropyl‐6‐methoxy‐4‐nitro‐1H‐benzo[d]imidazole.
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Scheme 31. 6‐Alkyl substitution by method A.
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6-Benzyl substitution
Method A (Scheme 31): the N1-alkylated benzimidazole 152a,b underwent catalytic
hydrogenation to reduce the nitro group to the corresponding amine, which formed
hydrochloride salt 155a,b. Benzylation of 155a,b under reductive alkylation gave 121a,b. One
side reaction was N1-debenzylation of 152b, thus lower yield was obtained for 121b. Many
methods were tried for demethoxylation of 121a,b. Treatment of 48% HBr gave exclusively
debenzylation at the 4-N position. Using BBr3 at low temperature gave only about 30% yield.
The phenol 156a,b were converted to tosylate 157 and triflate 159106, which both failed to couple
with simple alkyl or benzyl Grignard by Fe(acac)3 coupling.107Method B: an alternative route
was to keep the nitro group on the coupling partner (compound 162). The advantages were: 1)
48% HBr could be used for demethylation (Scheme 32). Indeed, under microwave heating in
48% HBr, 152a was converted to 161, which precipitated from the solution upon neutralization.
2) Triflate 162 had the electron-withdrawing nitro group on the ring instead of an unprotected
amino group. This was good for the organometallic coupling reaction stragety.

Scheme 32. Synthesis of compound 162.

Several methods were tried on the C-C coupling of triflate 162 (Table 5). Suzuki-Miyaura cross
coupling reaction with potassium benzyltrifluoroborates108 worked best. Under the literature
condition (refluxing for 24 hours), this coupling reaction was not completed. The reaction was
carried out in the microwave reactor at 100 °C, and it was completed in 1.5 hours.
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Table 5. Coupling reaction for C6‐C bond formation.

Substrate

Catalyst

Solvent

Temp./time

Result

1 (CH3)2CHCH2MgBr Fe(acac)3

THF/NMP rt, 2 h

No reaction

2 PhCH2MgBr

Ni(dppp)Cl2

THF

rt, 20 h

No reaction

3 PhCH2ZnBr

Pd2dba3

THF

Reflux, 20 h

Messy reaction

Pd(dppf)Cl2∙CH2Cl2
Pd(PPh3)4
Pd(OAc)2 & Xantphos
Pd(OAc)2 & DPEphos
4 PhCH2BF3K

Pd(dppf)Cl2∙CH2Cl2

THF/H2O

Reflux, 20 h

Product isolated,
reaction not completed

5 PhCH2BF3K

Pd(dppf)Cl2∙CH2Cl2

THF/H2O

Microwave

20% yield

1h

Non-commercially available potassium benzyltrifluoroborates 166a-c were made from the
Grignard.109 167b had lower yield, probably because of steric hindrance and electron
withdrawing effect of the o-fluoro substitution. Starting from the C-C coupling, compounds were
no longer common intermediates, so no further improvement of reaction conditions was made.
(Scheme 33) The flowing steps were similar to that of method A.
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Scheme 33. 6‐Benzyl substitution by method B.

6-Amino substitution
Direct coupling of the 2-aminobutan-1-ol or the TBS protected 2-aminobutan-1-ol with the
triflate 162 under several conditions was not successful. Fortunately, the C-N bond could be
formed by just changing the amine substrate to the benzophenone imine or oxazolidinone. Thus
two methods were developed to make the 6-aminobenzimidazoles.
In method C (Scheme 34), the coupling of the triflate 162 and 4-alkyloxazolidin-2-one 169a,b
was catalyzed by cesium carbonate, Pd2dba3, and Johnphos ligand at 105 °C, and afforded
170a,b in about 40% yield. This was based on a palladium catalyzed coupling reaction of aryl
chloride and oxazolidin-2-one reported in the literature.110 The benzylation at 6-position was
similar as in method A and B. Finally, oxazolidinone 172a,b was hydrolyzed under basic
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conditions to afford the target product 173a,b. Ethanolic KOH gave higher yield than NaOH in
methanol for the final hydrolysis. The oxazolidinone 169b was not commercially available, and
could be easily synthesized from the amino alcohol 174 by refluxing with potassium carbonate

Scheme 34. 6‐Amino substitution by Method C.

and diethyl carbonate111. However, the C-N coupling reaction of 4-isopropyloxazolidin-2-one
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169c gave only a very low yield of 170c. This might be due to the steric hindrance of the
isopropyl group, which made the coupling reaction very slow, and the triflate 162 was cleaved to
the corresponding phenol 161 under heating and basic conditions. The coupling reaction also
tended to give lower yield when scaled up. Different ligands (Xantphos, X-phos), base
(Zn[N(SiMe3)2]2), sovent (1,4-dioxane), using aryl other coupling partner instead of the triflate
(chloride or nanoflate), and other conditions (80 °C, microwave irradiation, Schlenk flask) were
tried, but none of them improved the yield of this reaction.
In method D (Scheme 35), the triflate 162 was coupled with benzophone imine 175 followed by
hydrolysis to afford the aniline 176 in 68% yield by two steps.112, 113 The 4-N-benzylation was
similar as in previous methods, but to differentiate between the amino groups between the 4- and
6-position, the 6-amino group of 176 was protected as trifluoroacetic amide with trifluoroacetic
anhydride and pyridine. After 4-N-benzylation, 179 was treated with sodium hydride to generate
the sodium salt, which could condense with triflate 180a,c,d to give 181a,c,d.114-116 The reaction
was always not completed even with excess amount of sodium hydride and triflate, and the
resulting product 181a,c,d was contaminated with a small amount of 179. The partially puried
181a,c,d was subsequently treated with sodium borohydride. Under this condition simultaneous
deprotection of the amine117, 118 and reduction of the ester to the alcohol were achieved, and the
desired final compounds 173a, 182 c,d were obtained. Triflate 180a-d was from α-hydroxy ester
183a-d115, 116, which was commercially available or synthesized from the α-amino acid 182ad.119
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Scheme 35. 6‐Amino substitution by Method D.
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Chapter 5
Summary
Tubulysin
The two γ-amino acids in the Tuv and Tup fragments of tubulysin were synthesized:
(R)-3-(Benzyloxycarbonylamino)-4-methylpentanoic acid (138).
(2S,4R)-4-(Tert-butoxycarbonylamino)-2-ethyl-5-phenylpentanoic acid (146a).
A noval Evans’ oxazolidinone strategy was developed for the stereoselective synthesis of Cbz-βhomovaline in Tuv fragment.
A crystal structure of the Tup fragment was obtained.

CDK5
5 target compounds and 31 noval intermediates were synthesized.
Target compounds synthesized:
N-Benzyl-6-(3-chlorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (120a).
N-Benzyl-6-(2-fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (120b).
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(R)-2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)-3-phenylpropan-1-ol
(173a).
2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)butan-1-ol (173b).
(R)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)-4-methylpentan-1-ol
(181c).
Compounds submitted or ready to submit for biological testing:
N-Benzyl-6-(3-chlorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (120a).
N-Benzyl-6-(2-fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (120b).
(R)-2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)-3-phenylpropan-1-ol
(173a).
2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)butan-1-ol (173b).
N-Benzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazol-4-amine (121a).
N,1-dibenzyl-6-methoxy-1H-benzo[d]imidazol-4-amine (121b).
(R)-4-Benzyl-3-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxazolidin-2-one
(172a).
3-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-4-ethyloxazolidin-2-one (172b).
Noval Synthetic stragety:
Palladium catalyzed coupling of aryl triflate with oxazolidinone (Scheme 34)
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Pharmocological activity:
The 6-benzylbenzimidazole series (120a,b) is not active against CDK5.
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Chapter 6

Experimental
All solvents and reagents were used as received unless noted otherwise. Tetrahydrofuran (THF)
was distilled from Na-benzophenone ketyl radical under a blanket of Argon prior to use. All
reactions were conducted in dry glassware and under an atmosphere of argon unless otherwise
noted. Melting points were determined on a MelTemp apparatus and are uncorrected. All
proton NMR spectra were obtained on a NMR with an Oxford spectrospin cryostat, a Bruker
Avance system, and were acquired using Bruker Topsin 2.0 acquisition software. Acquired FIDs
were analyzed using MestReC 3.2. Elemental analyses were conducted by Atlantic Microlabs.
All mass spectral analyses were conducted at the University of Pittsburgh regional mass spectral
facility. All 1H NMR spectra are reported as ppm relative to TMS and as an internal standard.
Coupling values are reported in Hertz.
3-Methylbutanoyl chloride (133). A dry 3 neck flask equipped with an internal thermometer
and an addition funnel was charged with isovaleric acid (10.2 g, 0.1 mol, 1.0 equiv),
dichloromethane (100 mL) and DMF (0.5 mL). This solution was cooled to 0 °C. Oxalyl
chloride (25.4 g, 0.2 mol, 2.0 equiv) was added slowly with the addition funnel over 25 min
maintaining the internal temperature at 0 – 5 °C. A bubble trap was used to observe gas
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generation. After addition, the reaction mixture was allowed to warm to room temperature and
stirred at room temperature for an additional 2 h. After evaporation of the solvent, the residue
was distilled to yield 6.3 g (52%) of the acyl chloride as a yellow oil. 1H NMR (300 MHz,
CDCl3): δ 2.79 (d, J = 6.6 Hz, 2H), 2.18 – 2.32 (m, 1H), 1.03 (d, J = 6.6 Hz, 6H).
(R)-4-Benzyl-3-(3-methylbutanoyl)oxazolidin-2-one (134). 2.13 M nbutyl lithium in hexane
(tirated with diphenylacetic acid) (6.6 mL, 14 mmol, 1.0 equiv) was added dropwise to a solution
of (R)-4-benzyloxazolidin-2-one (2.5 g, 14 mmol, 1.0 equiv) in THF (25 mL) at -78 °C over 20
min. Freshly distilled 3-methylbutanoyl chloride (133; 1.86 g, 15 mmol, 1.1 equiv) was added.
The reaction mixture was stirred at -78 °C for 20 min, allowed to warm to 0 °C, and stirring was
continued until the reaction was completed as shown by TLC. Saturated aqueous sodium
bicarbonate (10 mL) was added, and the mixture was allowed to warm to room temperature over
45 min. 10% aqueous sodium carbonate (20 mL) was added, and the mixture was extracted with
dichloromethane (30 mL × 3). The combined extracts were washed with brine and dried over
magnesium sulfate. Evaporation of the solvent gave a yellow oil, which was subjected to silica
gel column chromatography (hexanes/EtOAc 10:1 – 5:1) to afford 2.40 g (66%) of the desired
product as a white solid. Rf 0.87 (hexanes/EtOAc/EtOH 10:10:1). mp 44 °C (lit. mp 41°C). 1H
NMR (300 MHz, CDCl3): δ 7.22 – 7.33 (m, 5H), 4.66 – 4.72 (m, 1H), 4.13 – 4.23 (m, 2H), 3.32
(dd, J = 3.6, 13.4 Hz, 1H), 2.70 – 2.94 (m, 3H), 2.17 – 2.30 (m, 1H), 1.02 (dd, J = 5.1, 6.6 Hz,
6H).
(R)-Tert-butyl 3-((R)-4-benzyl-2-oxooxazolidine-3-carbonyl)-4-methylpentanoate (135). 1.0
M sodium hexamethyldisilylamide in THF (2.2 mL, 2.2 mmol, 1.1 equiv) was added dropwise to
a suspension of (R)-4-benzyl-3-(3-methylbutanoyl)oxazolidin-2-one (134, 0.523 g, 2 mmol, 1.0
equiv) in THF (10 mL) at -78 °C. This mixture was stirred at -78 °C for 1 h. Tert-butyl 277

bromoacetate (1.171 g, 6.0 mmol, 3.0 equiv) was added, and stirring was continued for 4 h until
the reaction was completed as shown by TLC. The mixture was warmed to 0 °C. Saturated
aqueous ammonium chloride (10 mL) was added, and the mixture was extracted with ethyl
acetate (10 mL × 3). The combined extracts were washed with brine and dried over magnesium
sulfate. Evaporation of the solvent gave a white solid, which was subjected to silica gel column
chromatography (hexanes/EtOAc 5:1) to afford 0.647 g (86 %) of 135 as a white solid. Rf 0.56
(hexanes/EtOAc 3:1). mp 133 °C (lit. mp 135.6 – 136.7 ºC ). [α] D25 -77.0 ° (c 1.00, CH2Cl2).
(lit. the enatiomer [α] D25 +69.6 °(c 1.00, CH2Cl2)). 1H NMR (300 MHz, CDCl3): δ 7.19 – 7.34
(m, 5H), 4.62 – 4.70 (m, 1H), 4.12 – 4.19 (m, 3H), 3.36 (dd, J = 12.6, 3.0 Hz, 1H), 2.70 – 2.88
(m, 2H), 2.45 (dd, J = 17.1, 3.6 Hz, 1H), 1.42 (s, 9H), 1.01 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9
Hz, 3H).
(R)-4-Tert-butoxy-2-isopropyl-4-oxobutanoic acid (136). 30 wt% hydrogen peroxide (0.66
mL, 6.72 mmol, 4 equiv) was added to a solution of (R)-tert-butyl 3-((R)-4-benzyl-2oxooxazolidine-3-carbonyl)-4-methylpentanoate (135; 630 mg, 1.68 mmol, 1 equiv) in THF (25
mL) at 0 °C. A solution of lithium hydroxide monohydrate (141 mg, 3.36 mmol, 2 equiv) in
deionized water (8 mL) was added dropwise over 30 min. This solution was stirred at 0 °C for
5.5 h until the reaction was completed (TLC). Saturated aqueous sodium sulfite (5 mL). Then
saturated aqueous sodium bicarbonate (5 mL) were added at 0 °C. After evaporation of THF in
vacuo, the resulting aqueous solution was diluted with water (10 mL), washed with
dichloromethane (10 mL × 4), acidified to pH 1.5 with 6 N aqueous HCl, and extracted with
ethyl acetate (10 mL × 4). The combined extracts were dried over magnesium sulfate.
Evaporation of the solvent gave a yellow oil, which was subjected to silica gel column
chromatography (hexanes/EtOAc 10:3) to afford 298 mg (82%) of the desired acid as a colorless
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oil. Rf 0.50 (hexanes/EtOAc/EtOH 8:2:1).

1

H NMR (300 MHz, CDCl3): δ 2.57 – 2.73 (m, 2H),

2.36 (dd, J = 14.4, 3 Hz, 1H), 1.98 – 2.05 (m, 1H), 1.43 (s, 9H), 0.96 (dd, J = 3.6, 6.9 Hz, 6H).
(R)-Tert-butyl 3-(benzyloxycarbonylamino)-4-methylpentanoate (137). Diphenyl phosphoryl
azide (192.6 mg, 0.70 mmol, 1.0 equiv) was added to a solution of (R)-4-tert-butoxy-2isopropyl-4-oxobutanoic acid (136; 151.8 mg, 0.70 mmol, 1.0 equiv) and triethylamine (77.9 mg,
0.77 mmol, 1.1 equiv) in toluene (10 mL). The mixture was stirred at room temperature for 30
min and then slowly heated to reflux. After refluxing for 3h, the reaction mixture was cooled to
50 °C, and benzyl alcohol (227.0 mg, 2.10 mmol, 3 equiv) was added. Then the reaction was
refluxed again for 2.5 h. After cooling to room temperature, saturated aqueous sodium
bicarbonate (15 mL) was added, and the mixture was extracted with diethyl ether (15 mL × 4).
The combined extracts were washed with brine and dried over sodium sulfate. Evaporation of
the solvent gave a colorless oil, which was subjected to silica gel column chromatography
(hexanes/EtOAc 15:1 – 10:1.50) to afford 73.8 mg (17%) of 137 as a colorless oil. Rf 0.43
(hexanes/EtOAc 5:1). 1H NMR (300 MHz, CDCl3): δ 7.17 – 7.41 (m, 5H), 5.00 – 5.15 (m, 3H),
3.74 – 3.84 (m, 1H), 2.33 – 2.46 (m, 2H), 1.71 – 1.73 (m, 1H), 1.40 (s, 9H), 0.90 (dd, J = 6.6, 1.5
Hz, 6H).
(R)-3-(Benzyloxycarbonylamino)-4-methylpentanoic acid (138). Dimethyl sulfide (143 mg,
2.3 mmol, 10 equiv) was added to a solution of (R)-tert-butyl 3-(benzyloxycarbonylamino)-4methylpentanoate (138; 73.8 mg, 0.23 mmol, 1 equiv) in 7:3 dichloromethane : TFA (v/v, 2.5
mL) at 0 °C. This solution was stirred at room temperature for 3 h. After evaporation of the
solvent, the residue was dissolved in dichloromethane (10 mL) and extracted with 1 N aqueous
sodium hydroxide (15 mL). The aqueous layer was washed with dichloromethane (15 mL × 2),
acidified to pH < 2 with 1 N aqueous HCl, and extracted with dichloromethane (10 mL × 2).
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The combined extracts were dried over magnesium sulfate. Evaporation of the solvent afforded
46.1 mg (76 %) of the desired acid as a white solid. 1H NMR (300 MHz, CDCl3): δ 7.19 – 7.35
(m, 5H), 5.09 – 5.13 (m, 3H), 3.77 – 3.86 (m, 1H), 2.56 – 2.58 (m, 2H), 1.52 – 1.90 (m, 1H),
0.93 (dd, J = 6.9, 1.8 Hz, 6H).
(R)-Benzyl 1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-3-ylcarbamate (139). (R)-3(Benzyloxycarbonylamino)-4-methylpentanoic acid (138; 45 mg, 0.17 mmol, 1 equiv) was
dissolved in dichloromethane (2 mL) and the solution was cooled to 0 °C. To this solution was
added EDCI (49 mg, 0.255 mmol, 1.5 equiv), HOBt (23 mg, 0.17 mmol, 1 equiv), N,Odimethylhydroxylamine hydrochloride (25 mg, 0.255 mmol, 1.5 equiv) and N-methylmorpholine
(81 mg, 0.8 mmol, 4.7 equiv). The mixture was stirred at room temperature overnight. Then it
was diluted with ethyl acetate (10 mL), washed subsequently with 1N aqueous HCl, brine and
saturated aqueous sodium bicarbonate, and dried over magnesium sulfate. Evaporation of the
solvent gave a colorless solid, which was subjected to silica gel column chromatography
(hexane/EtOAc) to afford 40 mg (89%) of a colorless oil. Rf 0.23 (hexanes/EtOAc 2:1). 1H
NMR (300 MHz, CDCl3): δ 7.24 – 7.33 (m, 5H), 5.06 (s, 2H), 5.49 (br, 1H), 3.64 (s, 3H), 3.12
(s, 3H), 2.53 – 2.76 (m, 2H), 1.90 – 1.94 (m, 1H), 0.88 – 0.92 (t, J = 5.4 Hz, 6H).
(R)-Tert-butyl 1-hydroxy-3-phenylpropan-2-ylcarbamate (47). A dry 3 neck flask equipped
with an internal thermometer, an overhead stirrer, and an addition funnel was charged with Lphenylalanine (4.956 g, 30 mmol, 1.0 equiv) and THF (50 mL). The mixture was cooled to 0 °C.
Sodium borohydride (2.269 g, 60 mmol, 2.0 equiv) was added in 0.25 g portions over 15 min.
Iodine (7.614 g, 30 mmol, 1.0 equiv) in THF (15 mL) was slowly added with the addition funnel
over 50 min maintaining the internal temperature at 0 – 10 °C. The mixture was stirred at 0 °C
for another 15 min. The reaction mixture was allowed to warm to room temperature and stirred
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for 2.5 h. Methanol (10 mL) was slowly added with water bath providing cooling. The mixture
was basified to pH 12 with 1N aqueous sodium hydroxide and extracted with diethyl ether (100
mL × 3). After evaporation of the solvent in vacuo, the residue was dissolved in THF (50 ml).
DMAP (93.1 mg, 0.76 mmol) and “Boc anhydride” (7.857 g, 36 mmol, 1.2 equiv) were added
and the mixture was stirred at room temperature for 40 min. The reaction mixture was extracted
with diethyl ether (100 mL × 3). The combined extracts were washed subsequently with
saturated aqueous sodium bicarbonate and brine, and dried over sodium sulfate. Evaporation of
the solvent a white solid, which was subjected to silica gel column chromatography
chromatography (Hexanes/EtOAc 2:1) to afford 3.0 g (40%) of 47 as a white solid. Rf 0.34
(Hexanes/EtOAc 2:1). mp 92 – 93 °C (lit. mp 94 – 95 ºC ). 1H NMR (300 MHz, CDCl3): δ 7.20
– 7.30 (m, 5H), 4.71 (s, 1H), 3.87 (br, 1H), 3.52 – 3.68 (m, 2H), 2.84 (d, J = 6.3 Hz, 2H), 1.414
(s, 9H).
(S,E)-Ethyl 4-(tert-butoxycarbonylamino)-2-methyl-5-phenylpent-2-enoate (70). A 3 neck
flask equipped with an overhead stirrer and an addition funnel was charged with (R)-tert-butyl 1hydroxy-3-phenylpropan-2-ylcarbamate (47; 2.010 g, 8 mmol, 1.0 equiv), Tempo (38 mg, 0.24
mmol, 0.03 equiv), sodium bromide (824 mg, 8 mmol, 1.0 equiv), water (4 mL) and
dichloromethane (40 mL). The mixture was cooled to 0 °C. A solution of 6% sodium
hypochlorite (22 g, 17.6 mmol, 2.0 equiv) and sodium bicarbonate (1.95 g, 23.2 mmol, 2.9
equiv) was added dropwise with the addition funnel over 1 h, and stirring was continued at 0 °C
for 2 h until the reaction was completed (TLC). The reaction mixture was extracted
dichloromethane (10 mL × 4). The combined extracts were washed subsequently with a solution
of potassium iodide (64 mg) in 10% aqueous potassium hydrogen sulfite (16 mL), 10% aqueous
sodium thiosulfate (20 mL) and brine, and dried over magnesium sulfate. Evaporation of the
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solvent gave 1.71g of a white solid, which was used within one day of preparation. Rf 0.63
(Hexanes/EtOAc 2:1). (Carbethoxyethylidene)triphenylphosphorane (1.59 g, 4.4 mmol, 1.1
equiv) was added to a solution of the aldehyde freshly prepared above (0.994 g, 4.0 mmol, 1.0
equiv) in dichloromethane (12 mL) at 0 °C. The mixture was allowed to slowly warm to room
temperature and stirring was continued overnight. Evaporation of the solvent gave a white solid,
which was subjected to silica gel column chromatography (hexane/EtOAc 10:1) to afford 0.729 g
(55 %) of the desired product as a white color solid. Rf 0.70 (Hexanes/EtOAc 2:1). mp 63.2 –
64.3 °C. [α]23 D +36 (c 1.39, CHCl3) (lit + 31.8). 1H NMR (300 MHz, CDCl3): δ 7.15 – 7.28 (m,
5H), 6.50 (dd, J = 9.6, 1.5 Hz, 1H), 4.64 (br, 1H), 4.55 (br, 1H), 4.17 (q, J = 7.2, Hz, 2H), 2.91
(dd, J = 13.5, 5.4 Hz, 1H), 2.77 (dd, J = 13.5, 7.2 Hz, 1H), 1.68 (d, J = 1.5, 3H), 1.39 (s, 9H),
1.27 (t, J = 7.2 Hz, 3H).
(S,E)-4-(Tert-butoxycarbonylamino)-2-methyl-5-phenylpent-2-enoic acid (145). 1 N
aqueous sodium hydroxide (7 mL, 7 mmol, 2.5 equiv) was added to a solution of (S,E)-ethyl 4(tert-butoxycarbonylamino)-2-methyl-5-phenylpent-2-enoate (70; 4.10 g, 12.3 mmol, 1 equiv) in
ethanol (40 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirring
was continued overnight. After evaporation of the solvent, the residue was dissolved in 1 N
aqueous sodium hydroxide (10 mL). This solution was washed with diethyl ether (5 mL × 2)
and acidified to pH < 3 with 2 N aqueous HCl. The white solid precipitant was collected by
filtration. The filtrate was extracted with diethyl ether (5 mL × 3). The combined extracts were
washed with brine and dried over sodium sulfate. Evaporation of the solvent gave a white solid,
which was combined with the white solid precipitant to afford 3.923 g (100%) of the desired
acid. Rf 0.47 (Hexanes/EtOAc 2:1). mp 140.0 – 140.5 °C. 1H NMR (300 MHz, CDCl3): δ 7.17
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– 7.33 (m, 5H), 6.65 (dd, J = 10.5, 1.5 Hz, 1H), 4.64 (br, 2H), 2.96 (dd, J = 12.6, 5.4 Hz, 1H),
2.80 (dd, J = 13.5, 7.2 Hz, 1H), 1.71 (d, J = 1.5, 3H), 1.43 (s, 9H).
(2S,4R)-4-(Tert-butoxycarbonylamino)-2-ethyl-5-phenylpentanoic acid (146a). (S,E)-4(Tert-butoxycarbonylamino)-2-methyl-5-phenylpent-2-enoic acid (145; 800 mg, 2.62 mmol )
was dissolved in methanol (20 mL) containing 10% Pd/C (20 mg). The hydrogenation flask was
evacuated and backfilled with hydrogen three times, and then shaken under 50 psi of a hydrogen
atmosphere for 16 h at room temperature. The mixture was filtered through Celite. Evaporation
of the solvent gave a white solid, which was recrystallized from diethyl ether and hexanes (1:1)
to afford 428 mg (53%) of 146a as colorless needle crystals. Rf 0.47 (Hexanes/EtOAc 2:1). mp
134.4 – 134.7 °C (lit mp 136 °C). [α]D23 13.2 (c 1, CHCl3) (lit [α]D23 13.3 (c 1, CHCl3). 1H
NMR (400 MHz, CDCl3): δ 7.15 – 7.32 (m, 5H), 6.25 (d, J = 7.2 Hz, 0.5H), 4.53 (d, J = 8.4 Hz,
1H), 3.85 – 4.00 (br m, 1H), 2.71 – 2.80 (m, 2H), 2.54 (br m, 1H), 1.84 (br m, 1H), 1.40 (s, 9H),
1.17 (d, J = 7.2 Hz, 3H).
1-benzyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (152b). N-methylmorpholine (40.5 mg,
0.4 mmol, 0.07 equiv), 1,2-dimethoxyethane (36.0 mg, 0.4 mmol, 0.07 equiv), and potassium
hydroxide powder (880 mg, 17.5 mmol, 2.9 equiv) were added to a solution of 5-methoxy-7nitro-1H-benzo[d]imidazole (1.15 g, 5.9 mmol, 1 equiv) in acetonitrile (200 mL). The mixture
was stirred at room temperature for 30 min. Benzyl bromide (1.03 g, 6 mmol, 1.01 equiv) was
added, and stirring was contiuned for 2.5 h. The mixture was filtered. The filtrate was
concentrated in vacuo to give a yellow solid, which was subjected to silica gel column
chromatography (hexane/EtOAc 2:3) to afford 920 mg (55 %) of the desired product as a yellow
solid. Rf 0.33 (Hexanes/EtOAc 2:1). mp 63.2 – 64.3 °C. 1H NMR (300 MHz, CDCl3): δ 8.09 (s,
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1H), 7.78 (d, J = 2.3 Hz, 1H), 7.16 – 7.38 (m, 5H), 7.05 (d, J = 2.3 Hz, 1H), 5.38 (s, 2H), 3.86 (s,
3H).
1-Isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (152a). A 500 mL one neck flask was
charged with 1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (5.0 g, 27.3 mmol, 1equiv),
sodium acetoxyborohydride (17.36 g, 81.9 mmol, 3 equiv), THF (100 mL), acetone (7.93 g, 137
mmol, 5 equiv) and formic acid (3.77 g, 81.9 mmol, 3 equiv). The mixture was stirred overnight.
The solvent was removed in vacuo, and the dark red residue was dissolved in formic acid (31
mL). Butylated hydroxytoluene (20 mg) was added, and the mixture was cooled to 0 °C. Then
concentrated HCl (87 mL) was added, and the mixture was quickly heated to reflux with a
heating mentle. After refluxing for 15 min, most of the solvent was removed in vacuo at 80 °C.
The aqueous solution was neutralized with 50% aqueous sodium hydroxide to pH 8 and
extracted with ethyl acetate (50 mL × 4). The combined extracts were washed with brine and
dried over sodium sulfate. Evaporation of the solvent gave a brown solid, which was subjected
to silica gel column chromatography (hexanes/EtOAc 1:1) to afford 4.5 g (74%) of the desired
product as a yellow solid. Rf 0.32 (CH2Cl2/MeOH/NH4OH 100:10:0.1). mp 127.2 – 128.1 °C.
1

H NMR (400 MHz, CDCl3): δ 8.12 (s, 1H), 7.21 (d, J = 2.3 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H),

4.58 – 4.65 (m, 1H), 3.95 (s, 3H), 1.65 (d, J = 6.8 Hz, 6H).
1-Isopropyl-6-methoxy-1H-benzo[d]imidazol-4-aminium chloride (155a). 1-Isopropyl-6methoxy-4-nitro-1H-benzo[d]imidazole (152a, 833 mg, 3.54 mmol) was dissolved in ethanol (42
mL) and chloroform (8 mL) containing 10% Pd/C (150 mg). The hydrogenation flask was
evacuated and backfilled with hydrogen three times, and then shaken under 55 psi of a hydrogen
atmosphere for 16 h at room temperature. The mixture was filtered through Celite and the Celite
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pad was washed with 1:1 dichloromethane : methanol (v/v). Evaporation of the solvent gave 841
mg (98%) of the salt as a light green solid.
N-Benzyl-1-isopropyl-6-methoxy-1H-benzo[d]imidazol-4-amine (121a). Sodium
acetoxyborohydride (608 mg, 2.87 mmol, 1 equiv) was added to a solution of 1-isopropyl-6methoxy-1H-benzo[d]imidazol-4-aminium chloride (155a, 832 mg, 2.87 mmol, 1equiv) in 1,2dichloroethane (10 mL) at room temperature. After stirring for 2 min, benzaldehyde (457 mg,
4.31 mmol, 1.5 equiv) was added. After stirring for 1 min, a second ammount of sodium
acetoxyborohydride (914 mg, 4.31 mmol, 1.5 equiv) was added and stirring was continued
overnight. Saturated aqueous sodium bicarbonate (8 mL) was added. The mixture was stirred
until bubbling was stopped and extracted with diethyl ether (10 mL × 3). The combined extracts
were washed with brine and dried over sodium sulfate. Evaporation of the solvent gave a brown
solid, which was subjected to silica gel column chromatography (Hexanes/EtOAc 2:1 to 1:2,
0.5% Et3N) to afford 790 mg (93%) of the product as a white solid. Rf 0.58
(CH2Cl2/MeOH/NH4OH 100:10:0.1). mp 81.8 – 83.9 °C. 1H NMR (400 MHz, CDCl3): δ 7.72
(s, 1H), 7.25 – 7.42 (m, 5H), 6.20 (d, J = 2.1 Hz, 1H), 6.03 (d, J = 2.1 Hz, 1H), 5.29 (t, J = 5.4
Hz, 1H), 4.47 – 4.53 (m, 1H), 3.80 (s, 3H), 1.59 (d, J = 6.8 Hz, 6H). Anal. Calcd for C18H21N3O:
C, 73.19; H, 7.17; N, 14.23. Found: C, 73.33; H, 7.03; N, 14.24.
N,1-dibenzyl-6-methoxy-1H-benzo[d]imidazol-4-amine (121b). 1-benzyl-6-methoxy-4-nitro1H-benzo[d]imidazole (152b, 813 mg, 2.87 mmol) was dissolved in ethanol (42 mL) and
chloroform (8 mL) containing 10% Pd/C (150 mg). The hydrogenation flask was evacuated and
backfilled with hydrogen three times, and then shaken under 55 psi of a hydrogen atmosphere for
22 h at room temperature. The mixture was filtered through Celite and the Celite pad was
washed with 1:1 dichloromethane : methanol (v/v). Evaporation of the solvent gave the salt as a
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light green solid, which was dissolved in in 1,2-dichloroethane (10 mL). To this solution,
sodium acetoxyborohydride (608 mg, 2.87 mmol, 1 equiv) was added. After stirring for 2 min,
benzaldehyde (457 mg, 4.31 mmol, 1.5 equiv) was added. After stirring for 1 min, a second
ammount of sodium acetoxyborohydride (914 mg, 4.31 mmol, 1.5 equiv) was added and stirring
was continued overnight. Saturated aqueous sodium bicarbonate (8 mL) was added. The
mixture was stirred until bubbling was stopped and extracted with diethyl ether (10 mL × 3).
The combined extracts were washed with brine and dried over sodium sulfate. Evaporation of
the solvent gave a brown solid, which was subjected to silica gel column chromatography
(Hexanes/EtOAc:Et3N 4:1:0.004 to 1:1.5:0.001) to afford 591 mg (60%) of the product was
afforded as a white solid. Rf 0.79 (CH2Cl2/MeOH/NH4OH 100:10:0.1). mp 125.5 – 126.5 °C.
1

H NMR (400 MHz, CDCl3): δ 7.68 (s, 1H), 7.16 – 7.42 (m, 10H), 6.07 (d, J = 2.4 Hz, 1H), 6.03

(d, J = 2.4 Hz, 1H), 5.42 (s, 1H), 5.42 (s, 2H), 4.47 (d, J = 4.8 Hz, 2H), 3.70 (s, 3H). Anal. Calcd
for C18H21N3O: C, 76.94; H, 6.16; N, 12.24. Found: C, 76.97; H, 6.08; N, 12.18.
1-Isopropyl-4-nitro-1H-benzo[d]imidazol-6-ol (161). A 50 mL microwave reactor tube was
charged with 1-isopropyl-6-methoxy-4-nitro-1H-benzo[d]imidazole (9; 1.00 g, 4.25 mmol) and
48% HBr (20 mL) and subjected to microwave irradiation at 120 ºC for 2.5 h. The solvent was
removed in vucuo. The resulting yellow solid was dissolved in minimum amount of water.
Sodium bicarbonate was added in small portions until the pH was 6. The mixture was filtered.
The yellow collected solid was washed with water and dried in vacuo to afford 0.92 g (97%) of
the desired compound 10. Rf 0.36 (CH2Cl2/MeOH/NH4OH 100:10:0.1). mp 206 – 207 °C. 1H
NMR (400 MHz, DMSO-d6): δ 10.16 (s, 1H), 8.45 (s, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.40 (d, J =
2.0 Hz, 1H), 4.68 − 4.75 (m, 1H), 1.50 (d, J = 6.8 Hz, 6H).
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1-Isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl trifluoromethanesulfonate (162). Potassium
carbonate (608.1 mg, 4.4 mmol, 2.0 equiv) was added to a solution of 1-isopropyl-4-nitro-1Hbenzo[d]imidazol-6-ol (10; 486.7 mg, 2.2 mmol, 1.0 equiv) and 4-nitrophenyl
trifluoromethanesulfonate (656.5 mg, 2.42 mmol, 1.1 equiv) in DMF (11mL). The suspension
was stirred at room temperature for 2 h. Then the reaction mixture was diluted with
dichloromethane (250 mL) and filtered. The filtrate was washed with water (100 mL ×4) and
brine, and dried over sodium sulfate. Evaporation of the solvent gave a yellow oil, which was
subjected to silica gel flash column chromatography (Hexanes/EtOAc/Et3N 1:1:0.005) to afford
673.0 mg of the triflate in 87% yield. Rf 0.42 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 128.4 –
129.6 °C. 1H NMR (400 MHz, CDCl3): δ 8.32 (s, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 2.0
Hz, 1H), 4.67 − 4.74 (m, 1H), 1.70 (d, J = 6.8 Hz, 6H). Anal. Calcd for C11H10F3N3O5S: C,
37.40; H, 2.85; N, 11.89. Found: C, 37.43; H, 2.79; N, 11.84.
General procedure for making potassium benzyltrifluoroborate 166a-c (Procedure B). A
dry single-neck round bottom flask was charged with trimethoxyborate (780 mg, 7.5 mmol, 1.5
equiv) and THF (10 mL). This solution was cooled to -78 ºC and (3-chlorobenzyl)magnesium
chloride 0.5 – 1.0 M in THF (5 mmol, 1.0 equiv) was added dropwise over 15 min. The mixture
was stirred at -78 ºC for 1h, and then allowed to warm to room temperature over 1h. The
resulting white slurry was cooled to 0 ºC and methanol (5 mL) was added dropwise over 5 min.
The nitrogen inlet was removed and 4.5 M aqueous potassium hydrogen fluoride (6.5 mL,
30mmol, 6.0 equiv) was added dropwise at 0 ºC. After addition, the mixture was stirred at 0 ºC
for 1h. The mixture was concentrated and then azeotroped with toluene three times at 60 ºC on
the rotovap and dried on high vacuum overnight to afford a white solid. This solid was broken
into a fine powder with a spatula and suspended in acetone (10 mL) on rotavap with rotation at
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atmosphere pressure for 5 min at 40 ºC. This suspension was filtered through Celite. Acetone (5
mL) was added to the remaining solid in the flask and the same procedure and repeated for two
times. The filtrate combined was concentrated on vacuum. The solid obtained was suspended in
diethyl ether (4 mL) and filtered. The solid collected was washed with diethyl ether (4 mL) and
dried in vacuo to afford the desired salt as a white solid.
Potassium (3-chlorobenzyl)trifluoroborate (166a). Following procedure B, 747 mg of the
desired salt (64%) was obtained. mp > 300 °C. 1H NMR (400 MHz, DMSO-d6): δ 7.08 –
7.11(m, 1H), 6.85 – 6.91 (m, 3H), 1.43 (br, 2H).
Potassium (2-fluorobenzyl)trifluoroborate (166b). Following procedure B, 498 mg (46%) of
the desired product was obtained. mp > 300 °C. 1H NMR (400 MHz, DMSO-d6): δ 7.05(t, J =
27.6 Hz 1H), 6.96 (s, 1H), 6.89 − 6.92 (m, 2H), 1.44 (br, 2H).
Potassium (4-fluorobenzyl)trifluoroborate (166c). Following procedure B, 399.6 mg of the
desired salt (37%) was obtained. mp 171.6 – 172.1 °C. 1H NMR (400 MHz, DMSO-d6): δ 6.94
− 6.97 (m, 2H), 6.81 − 6.84 (m, 2H), 1.41 (br, 2H).
6-(3-Chlorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (167a). A 10 mL dry
microwave reactor tube with a stir bar was charged with 1-isopropyl-4-nitro-1Hbenzo[d]imidazol-6-yl trifluoromethanesulfonate (11; 176.6 mg, 0.50 mmol, 1.0 equiv),
potassium (3-chlorobenzyl)trifluoroborate (17a; 137.5 mg, 0.59 mmol, 1.18 equiv), cesium
carbonate (485.7 mg, 1.50 mmol, 3.0 equiv) and PdCl2(dppf)·CH2Cl2 (41.0 mg, 0.05 mmol, 0.1
equiv). The microwave reactor tube was capped with a rubber septum, evacuated and back filled
with nitrogen three times. Degassed D.I. water (0.5 mL) and THF (5 mL) were added via
syringe. The rubber septum was quickly replaced with the microwave reactor tube cap, and the
88

mixture was subjected to microwave irradiation at 100 ºC for 2.5 h. After cooled down to room
temperature, the mixture was filtered through Celite. The filtrate was extracted with EtOAc.
The combined extracts were washed with brine and dried over magnesium sulfate. Evaporation
of the solvent gave a brown solid, which was subjected to silica gel flash column
chromatography (Hexanes/EtOAc/Et3N 1:1:0.005) to afford 673.0 mg of the desired product in
70% yield. Rf 0.37 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 136.7 – 137.1 °C. 1H NMR
(CDCl3): δ 8.18 (s, 1H), 8.01 (s, 1H), 7.49 (s, 1H), 7.23 (m, 2H), 7.18 (s, 1H), 7.09 (d, J = 7.5
Hz, 1H), 4.61 − 4.67 (m, 1H), 4.16 (s, 2H), 1.63 (d, J = 7.0 Hz, 6H).
6-(2-Fluorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (167b). A dry microwave
reactor tube with a stir bar was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl
trifluoromethanesulfonate (11; 212.0 mg, 0.60 mmol, 1.0 equiv), potassium (2fluorobenzyl)trifluoroborate (17b; 155.4 mg, 0.72 mmol, 1.2 equiv), cesium carbonate (586.4
mg, 1.80 mmol, 3.0 equiv) and PdCl2(dppf)·CH2Cl2 (50.0 mg, 0.06 mmol, 0.1 equiv). The
microwave reactor tube was capped with a rubber septum, evacuated by back filled with nitrogen
three times. Degassed D.I. water (0.6 mL) and THF (6 mL) were added via syringe. The rubber
septum was quickly replaced with the microwave reactor tube cap, and the mixture was
subjected to microwave irradiation at 100 ºC for 1.5 h. After cooled down to room temperature,
the mixture was filtered through Celite. The filtrate was extracted with EtOAc. The combined
extracts were washed with brine and dried over magnesium sulfate. Evaporation of the solvent
gave a brown solid, which was subjected to silica gel flash column chromatography
(Hexanes/EtOAc/Et3N 1:1:0.005) to afford 72 mg of the desired product in 38% yield. Rf 0.36
(CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 124.8 – 125.1 °C. 1H NMR (CDCl3): δ 8.16 (s, 1H),
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8.03 (s, 1H), 7.58 (s, 1H), 7.18 − 1.25 (m, 2H), 7.04 − 7.11 (m, 2H), 4.62 − 4.68 (m, 1H), 4.19 (s,
2H), 1.63 (d, J = 6.8 Hz, 6H).
6-(4-Fluorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (167c). A dry microwave
reactor tube with a stir bar was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl
trifluoromethanesulfonate (11; 176.6 mg, 0.50 mmol, 1.0 equiv), potassium (2fluorobenzyl)trifluoroborate (17c; 129.6 mg, 0.60 mmol, 1.2 equiv), cesium carbonate (485.7
mg, 1.50 mmol, 3.0 equiv) and PdCl2(dppf)·CH2Cl2 (41.0 mg, 0.05 mmol, 0.1 equiv). The
microwave reactor tube was capped with a rubber septum, evacuated by back filled with nitrogen
three times. Degassed D.I. water (0.5 mL) and THF (5 mL) were added via syringe. The rubber
septum was quickly replaced with the microwave reactor tube cap, and the mixture was
subjected to microwave irradiation at 100 ºC for 3 h. After cooled down to room temperature,
the mixture was filtered through Celite. The filtrate was extracted with EtOAc. The combined
extracts were washed with brine and dried over magnesium sulfate. Evaporation of the solvent
gave a brown solid, which was subjected to silica gel flash column chromatography
(Hexanes/EtOAc/Et3N 1:1:0.005) to afford 91 mg of the desired product in 58% yield. Rf 0.42
(CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (CDCl3): δ 8.18 (s, 1H), 7.99 (d, J = 2.0 Hz, 1H),
7.58 (s, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.15 − 7.18 (m, 2H), 6.98 − 7.03 (m, 2H), 4.62 − 4.68 (m,
1H), 4.17 (s, 2H), 1.63 (d, J = 8.5 Hz, 6H).
6-(3-Chlorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-aminium chloride (168a). 6-(3Chlorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (18a; 105 mg, 0.318 mmol) was
dissolved in ethanol (40 mL) and chloroform (4 mL) containing 5% Pd/C (20 mg). The
hydrogenation flask was evacuated and backfilled with hydrogen 3 times, and then shaken under
50 psi of a hydrogen atmosphere overnight. The mixture was filtered through Celite, and the
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Celite pad was washed with 1:1 methanol : dichloromethane (v/v). Evaporation of the solvent
afforded 115.7 mg of the desired product in 100% yield. 1H NMR (DMSO-d6): δ 9.45 (s, 1H),
7.30 − 7.34 (m, , 2H), 7.22 − 7.27 (m, 2H), 7.09 (s, 1H), 6.54 (s, 1H), 4.81 − 4.88 (m, 1H), 3.99
(s, 2H), 1.58 (d, J = 6.4 Hz, 6H).
6-(2-Fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-aminium chloride (168b). 6-(4Fluorobenzyl)-1-isopropyl-4-nitro-1H-benzo[d]imidazole (18b; 50.1 mg, 0.16 mmol) was
dissolved in ethanol (20 mL) and chloroform (4 mL) containing 10% Pd/C (10 mg). The
hydrogenation flask was evacuated and backfilled with hydrogen 3 times, and then shaken under
50 psi of a hydrogen atmosphere overnight. The mixture was filtered through Celite, and the
Celite pad was washed with 1:1 methanol : dichloromethane (v/v). Evaporation of the solvent 52
mg of the desired product in 100% yield. 1H NMR (DMSO-d6): δ 9.47 (s, 1H), 7.27 − 7.34 (m,
2H), 7.13 − 7.18 (m, 2H), 7.03 (s, 1H), 6.55 (s, 1H), 4.80 − 4.86 (m, 1H), 4.01 (s, 2H), 1.57 (d, J
= 7.0 Hz, 6H).
N-Benzyl-6-(3-chlorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (120a). A dry round
bottom flask was charged with 6-(3-chlorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-aminium
chloride (19a; 78.9 mg, 0.235 mmol, 1.0 equiv), sodium triacetoxyborohydride (124.5 mg, 0.588
mmol, 2.5 equiv), bezaldehyde (37.4 mg, 0.353 mmol, 1.5 equiv) and 1,2- dichloroethane (2
mL). The mixture was stirred at room temperature overnight. After quenching with saturated
aqueous sodium bicarbonate (2 mL), the mixture was extracted with diethyl ether. The
combined extracts were washed with brine and dried over magnesium sulfate. Evaporation of
the solvent gave a brown solid, which was subjected to silica gel flash column chromatography
(Hexanes/EtOAc/Et3N 1:1:0.005) to afford 35 mg of the desired product in 38% yield as an oil.
Rf 0.34 (CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (CDCl3): δ 7.77 (s, 1H), 7.02 − 7.38 (m,
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9H), 6.53 (s, 1H), 6.18 (d, J = 0.8 Hz, 1H), 5.30 (t, 1H), 4.47 − 4.54 (m, 1H), 4.46 (d, 2H), 3.95
(s, 2H), 1.56 (d, J = 6.8 Hz, 6H). 1 was desolved in a minimal amount of diethyl ether, and
ethereal HCl was added dropwise. The solid precipitated as the hydrochloride salt. mp 206.2 –
207.9 °C. Anal. Calcd for C24H24ClN3·HCl·1/4H2O: C, 67.61; H, 5.91; N, 9.86. Found: C,
66.78; H, 5.96; N, 9.87.
N-Benzyl-6-(2-fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-amine (120b). A dry round
bottom flask was charged with 6-(2-fluorobenzyl)-1-isopropyl-1H-benzo[d]imidazol-4-aminium
chloride (19b; 49.8 mg, 0.16 mmol, 1.0 equiv), sodium triacetoxyborohydride (50.9 mg, 0.24
mmol, 1.5 equiv), benzaldehyde (20.9 mg, 0.197 mmol, 1.2 equiv) and 1,2- dichloroethane (1
mL). The mixture was stirred at room temperature for 24 h. After quenching with saturated
aqueous sodium bicarbonate (1 mL), the mixture was extracted with diethyl ether. The
combined extracts were washed with brine and dried over magnesium sulfate. Evaporation of
the solvent gave an orange oil, which was subjected to silica gel flash column chromatography
(Hexanes/EtOAc/Et3N 1:1:0.005) to afford 20 mg of the desired product in 34% yield. Rf 0.59
(CH2Cl2/MeOH/NH4OH 100:10:0.1). 2 was desolved in a minimal amount of diethyl ether, and
ethereal HCl was added dropwise. 1H NMR (CDCl3): δ 7.76 (s, 1H), 6.97 − 7.39 (m, 9H), 6.53
(s, 1H), 6.24 (s, 1H), 5.26 (t, 1H), 4.48 − 4.53 (m, 1H), 4.45 (s, 2H), 4.01 (s, 2H), 1.56 (d, J = 2.0
Hz, 6H). The solid precipitated as the hydrochloride salt. mp 166.3 – 167.8 °C. Anal. Calcd for
C24H24FN3·HCl: C, 70.32; H, 6.15; N, 10.25. Found: C, 70.12; H, 6.18; N, 10.15.
(R)-4-Benzyl-3-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)oxazolidin-2-one (170a). A
dry 5 ml disposable microwave reactor tube was charged with 1-isopropyl-4-nitro-1Hbenzo[d]imidazol-6-yl trifluoromethanesulfonate (162, 353.3 mg, 1 mmol, 1.0 equiv), (R)-4benzyloxazolidin-2-one (194.9 mg, 1.1 mmol, 1.1 equiv), Johnphos (23.9 mg, 0.08 mmol, 0.08
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equiv), Pd2dba3 (18.3 mg, 0.02 mmol, 0.02 equiv) and cesium carbonate (456.1 mg, 1.4 mmol,
1.4 equiv). The tube was sealed with a plastic microwave septum and then evacuated and back
filled with argon; this sequence was repeated two additional times. Toluene (2 mL) was added
via syringe. The reaction mixture was heated with an oil bath (bath temperature 100 – 110 °C)
for 18 h. After cooling, the reaction mixture was diluted with dichloromethane (20 mL) and
filtered through Celite. Evaporation of the solvent gave a brown oil, which was subjected to
silica gel column chromatography (hexanes/EtOAc 1:3) to afford 173 mg (45%) of the desired
product as a yellow oil. Rf 0.26 (CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (400 MHz,
CDCl3): δ 8.41 (d, J = 2.0 Hz, 1H), 8.24 (s, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.13 – 7.32 (m, 5H),
4.79 – 4.85 (m, 1H), 4.69 – 4.76 (m, 1H), 4.44-4.50 (t, J = 8.4 Hz, 1H), 4.33 (dd, J = 8.8, 4.4 Hz,
1H), 3.19 (dd, J = 13.6, 3.6 Hz, 1H), 2.88 (dd, J = 14.0, 8.8 Hz, 1H), 1.68 (dd, J = 8.8, 6.8 Hz,
6H).
(R)-3-(4-Amino-1-isopropyl-1H-benzo[d]imidazol-6-yl)-4-benzyloxazolidin-2-one (171a).
(R)-4-Benzyl-3-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)oxazolidin-2-one (170a; 59 mg,
0.16 mmol) was dissolved in ethanol (30 mL) containing 10% Pd/C (10 mg). The hydrogenation
flask was evacuated and backfilled with hydrogen three times, and then shaken under 50 psi of a
hydrogen atmosphere for 16 h at room temperature. The mixture was filtered through Celite.
Evaporation of the solvent gave a white solid, which was subjected to silica gel column
chromatography (EtOAc/hexanes 3:1, 1% Et3N) to afford 50 mg (91%) of the desired product as
a white solid. mp 158-160 °C. [α]D23 13.5 (c 2.41, CHCl3). Rf 0.24 (EtOAc/Et3N 100:1). 1H
NMR (400 MHz, CDCl3): δ 7.87 (s, 1H), 7.11 – 7.32 (m, 5H), 7.04 (d, J = 2.0 Hz, 1H), 6.59 (d, J
= 2.0 Hz, 1H), 4.54 – 4.60 (m, 2H), 4.46 (s, 2H), 4.36 (t, J = 4.0 Hz, 1H), 4.20 (dd, J = 13.5, 9.6
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Hz, 1H), 3.16 (dd, J = 13.2, 3.6 Hz, 1H), 2.78 (dd, J = 13.6, 9.6 Hz, 1H), 1.62 (dd, J = 12, 6.8
Hz, 6H).
(R)-4-Benzyl-3-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)oxazolidin-2-one
(172a). Benzaldehyde (19 mg, 0.18 mmol, 1.3 equiv) and sodium acetoxyborohydride (43 mg,
0.20 mmol, 1.5 equiv) were added to a solution of (R)-3-(4-amino-1-isopropyl-1Hbenzo[d]imidazol-6-yl)-4-benzyloxazolidin-2-one (171a, 47 mg, 0.14 mmol, 1.0 equiv) in 1,2dichloroethane (1 mL). The mixture was stirred at room temperature overnight. 1N aqueous
HCl (0.5 mL) was added and the mixture was stirred for 5 min. Saturated aqueous sodium
bicarbonate (0.5 mL) was added, and the mixture was stirred for 2 h, then brought to pH 9 with
5% aqueous potassium carbonate and extracted with dichloromethane (2 mL × 3). The
combined extracts were washed with brine and dried over magnesium sulfate. Evaporation of
the solvent gave a brown oil, which was subjected to silica gel column chromatography
(hexanes/EtOAc 1:1 to 1:3 with 0.5% Et3N) to afford 25 mg (42%) of the product as a white
solid. Rf 0.26 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 70-72 °C. 1H NMR (400 MHz, CDCl3):
δ 7.86 (s, 1H), 7.25 – 7.47 (m, 5H), 7.09 (d, J = 2.0 Hz, 1H), 6.95 (dd, J = 7.2, 1.6 Hz, 2H), 6.28
(d, J = 1.6 Hz, 1H), 5.48 (t, J = 5.6 Hz, 1H), 4.55 – 4.62 (m, 3H), 4.40 – 4.46 (m, 1H), 4.28 (t, J
= 8.0 Hz, 1H), 4.13 (dd, J = 8.4, 4.8 Hz, 1H), 3.01 (dd, J = 13.6, 3.2 Hz, 1H), 2.63 (dd, J = 14, 10
Hz, 1H), 1.63 (dd, J = 12, 6 Hz, 6H).
(R)-2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)-3-phenylpropan-1-ol
(173a). A solution of (R)-4-benzyl-3-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6yl)oxazolidin-2-one (172a; 25 mg, 0.057 mmol) in 5% ethanolic potassium hydroxide (3 mL)
was stirred at room temperature for 36 h. 5% Ethanolic potassium hydroxide (3 mL) was added,
and stirring was continued for 18h. Then the reaction mixture was heated with an oil bath (bath
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temperature 35 °C) for 30 min. Ethanol was removed in vacuo at 40 °C. Water (5 mL) was
added, and the mixture was extracted with dichloromethane (5 mL × 3). The combined extracts
were washed with brine and dried over magnesium sulfate. Evaporation of the solvent gave a
brown solid, which was subjected to silica gel column chromatography (hexanes/EtOAc 1:3,
0.5% Et3N) to afford 22 mg (94%) of the desired product as a slightly brown foam. Rf 0.02
(CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (400 MHz, CDCl3): δ 7.63 (s, 1H), 7.20 – 7.42
(m, 5H), 7.13 (d, J = 6.8 Hz, 2H), 6.00 (s, 1H), 5.76 (d, J = 1.6 Hz, 1H), 5.31 (t, J = 5.2 Hz, 1H),
4.39 – 4.46 (m, 3H), 3.70 (d, J = 8.4 Hz, 2H), 4.47 (dd, J = 11.6, 6.8 Hz, 1H), 2.92 (dd, J = 13.6,
4.8 Hz, 1H), 2.81 (dd, J = 13.6, 7.2 Hz, 1H), 1.56 (dd, J = 6.4, 2.4 Hz, 6H).
4-Ethyl-3-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)oxazolidin-2-one (170b). A dry
Shlenk flask with argon inlet was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl
trifluoromethanesulfonate (162, 353.3 mg, 1 mmol, 1.0 equiv), 4-ethyloxazolidin-2-one (127 mg,
1.1 mmol, 1.1 equiv), Johnphos (23.9 mg, 0.08 mmol, 0.08 equiv), Pd2dba3 (18.3 mg, 0.02
mmol, 0.02 equiv) and cesium carbonate (456.1 mg, 1.4 mmol, 1.4 equiv). The flask was capped
with a rubber septum, evacuated and back filled with argon; this sequence was repeated two
additional times. Toluene (2 mL) was added via syringe. Then the rubber septum was quickly
replaced by a glass cap, the joint was sealed with Teflon tape, and the argon inlet was closed.
The reaction mixture was heated with an oil bath (bath temperature 100 – 110 °C) for 18 h.
After cooling, the reaction mixture was diluted with dichloromethane (20 mL) and filtered
through Celite. Evaporation of the solvent gave a brown oil, which was subjected to silica gel
column chromatography (EtOAc) to afford 129 mg (41%) of the desired product as a yellow oil.
Rf 0.23 (CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (500 MHz, CDCl3): δ 8.36 (d, J = 2.0 Hz,
1H), 8.23 (s, 1H), 7.95 (d, J = 2.0 Hz, 1H), 4.69 – 4.74 (m, 1H), 4.56 – 4.64 (m, 2H), 4.25 (dd, J
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= 4.1, 7.9 Hz, 1H), 1.80 – 1.87 (m, 1H), 1.72 – 1.79 (m, 1H), 1.67 (dd, J = 6.8, 13.0 Hz, 6H),
0.95 (t, J = 7.5 Hz, 3H).
3-(4-Amino-1-isopropyl-1H-benzo[d]imidazol-6-yl)-4-ethyloxazolidin-2-one (171b). 4-Ethyl3-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)oxazolidin-2-one (170b; 162 mg, 0.51 mmol)
was dissolved in ethanol (40 mL) containing 10% Pd/C (30 mg). The hydrogenation flask was
evacuated and backfilled with hydrogen three times, and then shaken under 50 psi of a hydrogen
atmosphere for 16 h at room temperature. The mixture was filtered through Celite. Evaporation
of the solvent gave a brown solid, which was subjected to silica gel column chromatography
(EtOAc/EtOH 20:1, 0.5% Et3N) to afford 116 mg (79%) of the desired aniline as a red solid. Rf
0.21 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 193-195 °C. 1H NMR (400 MHz, CDCl3): δ 7.83
(s, 1H), 6.96 (d, J = 1.8 Hz, 1H), 6.48 (d, J = 1.8 Hz, 1H), 4.51 – 4.58 (m, 1H), 4.41 (s, 2H), 4.32
– 4.38 (m, 1H), 4.15 (dd, J = 5.6, 8.5 Hz, 1H), 1.69 – 1.80 (m, 1H), 1.55 – 1.68 (m, 7H), 1.67
(dd, J = 6.8, 13.0 Hz, 6H), 0.90 (t, J = 7.5 Hz, 3H).
3-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-4-ethyloxazolidin-2-one (172b).
Benzaldehyde (51 mg, 0.48 mmol, 1.2 equiv) and sodium acetoxyborohydride (127 mg, 0.60
mmol, 1.5 equiv) were added to a solution of 3-(4-amino-1-isopropyl-1H-benzo[d]imidazol-6yl)-4-ethyloxazolidin-2-one (171b, 115 mg, 0.40 mmol, 1.0 equiv) in 1,2-dichloroethane (1 mL).
The mixture was stirred at room temperature overnight. 1N HCl (0.5 mL) was added to quench
the reaction. The mixture was basified to pH 9 with 1N aqueous sodium hydroxide and extracted
with dichloromethane (10 mL × 3). The combined extracts were washed with brine and dried
over magnesium sulfate. Evaporation of the solvent gave a brown solid, which was subjected to
silica gel column chromatography (hexanes/EtOAc 1:3, 0.5% Et3N) to give a red solid. This
material was recrystallized from hot ethyl acetate and hexanes to afford 117 mg (77%) of the
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product as a pink solid. Rf 0.47 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 145 °C. 1H NMR (400
MHz, CDCl3): δ 7.82 (s, 1H), 7.23 – 7.41 (m, 5H), 6.98 (d, J = 1.8 Hz, 1H), 6.15 (d, J = 1.7 Hz,
1H), 5.40 (t, J = 5.7 Hz, 1H), 4.46 – 4.57 (m, 4H), 4.18 – 4.21 (m, 1H), 4.08 (dd, J = 5.7, 8.4 Hz,
1H), 1.53 – 1.61 (m, 7H), 1.43 – 1.51 (m, 1H), 0.77 (t, J = 7.5 Hz, 3H). Anal. Calcd for
C22H26N4O2: C, 69.82; H, 6.92; N, 14.80. Found: C, 69.74; H, 6.92; N, 14.80.
2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)butan-1-ol (173b). 10 N
aqueous sodium hydroxide (0.04 mL, 4 mmol) was added to a solution of 3-(4-(benzylamino)-1isopropyl-1H-benzo[d]imidazol-6-yl)-4-ethyloxazolidin-2-one (172b; 78 mg, 0.21 mmol) in
ethanol (0.5 mL). The mixture was heated with an oil bath (bath temperature 53-54 °C) for 20 h.
Again 10 N aqueous sodium hydroxide (0.04 mL, 4 mmol) was added, and stirring was
continued for another 6h. After cooling, the mixture was concentrated in vacuo, diluted with
water (5 mL), and extracted with dichloromethane (5 mL × 3). The combined extracts were
washed with brine, and dried over magnesium sulfate. Evaporation of the solvent gave a brown
solid, which was subjected to silica gel column chromatography (hexanes/EtOAc 1:3 – EtOAc,
0.5% Et3N) to afford 39 mg (54%) of the desired product as a slightly brown foam. Rf 0.29
(CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (400 MHz, CDCl3): δ 7.63 (s, 1H), 7.23 – 7.34
(m, 5H), 5.99 (d, J = 1.9 Hz, 1H), 5.76 (d, J = 1.8 Hz, 1H), 5.24 (t, J = 5.3 Hz, 1H), 4.41 – 4.47
(m, 3H), 3.75 (dd, J = 4.1, 10.7 Hz, 1H), 3.48 (dd, J = 6.2, 10.9 Hz, 1H), 3.35 – 3.41 (m, 1H),
2.06 (br, 1H), 1.51 – 1.59 (m, 8H), 0.94 (t, J = 7.5 Hz, 3H). m/z calcd for C21H28N4O 352.2,
found 352.2.
Isopropyl-4-nitro-1H-benzo[d]imidazol-6-amine (176). A dry 5 ml disposable microwave
reactor tube was charged with 1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl
trifluoromethanesulfonate (162, 353 mg, 1 mmol, 1.0 equiv), Xantphos (58 mg, 0.1 mmol, 0.1
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equiv), Pd2dba3 (23 mg, 0.025 mmol, 0.025 equiv) and cesium carbonate (814 mg, 2.5 mmol, 2.5
equiv). The tube was sealed with a plastic microwave septum and then evacuated and back filled
with argon; this sequence was repeated two additional times. Toluene (2 mL) and benzophenone
imine (236 mg, 1.3mmol, 1.3 equiv) were subsequently added via syringe. The mixture was
subjected to microwave irradiation at 150 °C for 30 min. After cooling, the reaction mixture was
diluted with ethyl acetate (20 mL) and filtered through Celite. Evaporation of the solvent gave a
brown oil, which was dissolved in methanol (10 mL). To this solution, hydroxylamine
hydrochloride (209 mg, 3mmol, 3 equiv) and acetic acid, sodium salt (328 mg, 4 mmol, 4 equiv)
were added. The mixture was stirred at room temperature for 30 min. Methanol was removed in
vacuo. To this residue, water (10 mL) was added. The mixture was acidified with 2 N aqueous
HCl to pH 1, washed with dichloromethane (3 mL × 2), basified to pH 11 with 50% aqueous
sodium hydroxide, and extracted with dichloromethane (5 mL × 3). The combined extracts were
washed with brine and dried over sodium sulfate. Evaporation of the solvent afforded 150 mg
(68%) of the desired aniline as a red foam. Rf 0.24 (CH2Cl2/MeOH/NH4OH 100:10:0.1). 1H
NMR (500 MHz, CDCl3): δ 8.02 (s, 1H), 7.55 (d, J = 2.0 Hz, 1H), 6.96 (d, J = 2.1 Hz, 1H), 4.524.57 (m, 1H), 3.94 (s, 2H), 1.63(d, J = 6.8 Hz, 6H).
2,2,2-Trifluoro-N-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)acetamide (177). Pyridine
(800 mg, 10.1 mmol, 3.0 equiv) was added to a solution of 1-isopropyl-4-nitro-1Hbenzo[d]imidazol-6-amine (12; 742 mg, 3.37 mmol, 1.0 equiv) in dichloromethane (20 mL).
The mixture was cooled to 0 °C, and trifluoroacetic anhydride (1.557 g, 7.41 mmol, 2.2 equiv)
was added dropwise. The reaction mixture was stirred at 0 °C for 3 h, quenched with saturated
aqueous ammonium chloride (10 mL), diluted with water (40 mL), acidified to pH 3 by 2 N
aqueous HCl, and extracted with ethyl acetate (50 mL × 3). The combined extracts were washed
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with brine and dried over sodium sulfate. Evaporation of the solvent gave a yellow solid, which
was subjected to silica gel column chromatography (hexanes/EtOAc 1:3) to afford 988 mg 93%)
of the product as a yellow solid. Rf 0.29 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 206 – 207 °C.
1

H NMR (400 MHz, CDCl3): δ 8.60 (d, J = 1.9 Hz, 1H), 8.37 (s, 1H), 8.06 (d, J = 2.0 Hz, 1H),

8.33 (br, 1H), 4.41 – 4.78 (m, 1H), 1.70 (d, J = 6.8 Hz, 6H). Anal. Calcd for C12H11F3N4O3: C,
45.58; H, 3.51; N, 17.72. Found: C, 45.72; H, 3.53; N, 17.72.
1-Isopropyl-6-(2,2,2-trifluoroacetamido)-1H-benzo[d]imidazol-4-aminium chloride (178).
2,2-Trifluoro-N-(1-isopropyl-4-nitro-1H-benzo[d]imidazol-6-yl)acetamide (177; 76 mg, 0.24
mmol) was dissolved in ethanol (35 mL) and chloroform (3 mL) containing 10% Pd/C (15 mg).
The hydrogenation flask was evacuated and backfilled with hydrogen three times, and then
shaken under 50 psi of a hydrogen atmosphere overnight at room temperature. The mixture was
filtered through Celite, and the Celite pad was washed with 1:1 methanol: dichloromethane.
Evaporation of the solvent gave 78 mg (100%) of the product as a yellow solid. 1H NMR (400
MHz, DMSO-d6): δ 11.35 (s, 1H), 9.51 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 7.03 (d, J = 1.5 Hz,
1H), 4.73 – 4.83 (m, 1H), 1.58 (d, J = 6.7 Hz, 6H). Anal. Calcd for C12H14ClF3N4O·1/2MeOH:
C, 44.01; H, 5.11; N, 15.79. Found: C, 44.03; H, 4.50; N, 16.17.
N-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2-trifluoroacetamide (179).
A dry flask was charged with 1-isopropyl-6-(2,2,2-trifluoroacetamido)-1H-benzo[d]imidazol-4aminium chloride (178; 65 mg, 0.20 mmol, 1.0 equiv), 1,2-dichloroethane (0.8 mL) and
benzaldehyde (25.6 mg, 0.24 mmol, 1.2 equiv). The mixture was stirred for 5 min until all solids
were dissolved. Sodium acetoxyborohydride (64 mg, 0.30 mmol, 1.5 equiv) was added, and the
mixture was stirred at room temperature for 20 h. Benzaldehyde (3.2 mg, 0.03 mmol) and
sodium acetoxyborohydride (20 mg, 0.09 mmol) were added and stirring was continued for 2 h.
99

Saturated aqueous sodium bicarbonate (10 mL) was added, and the mixture was extracted with
ethyl acetate (10 mL × 3). The combined extracts were washed with brine and dried over sodium
sulfate. Evaporation of the solvent gave a brown oil, which was subjected to silica gel column
chromatography (hexane/EtOAc 1:2, 0.5% Et3N) to afford a slightly pink solid. This material
was recrystallized from hot ethyl acetate and hexanes to give 49 mg (65%) of the desired product
as white needle crystals. Rf 0.32 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 176.2 – 178.4 °C. 1H
NMR (500 MHz, CDCl3): δ 7.82 (s, 1H), 7.81 (br, 1H), 7.44 (d, J = 1.5 Hz, 1H), 7.28 – 7.44 (m,
5H), 6.13 (d, J = 1.5 Hz, 1H), 5.41 (t, J = 5.5 Hz, 1H), 4.54 – 4.59 (m, 1H), 4.49 (d, J = 5.5 Hz,
2H), 1.60 (d, J = 6.7 Hz, 6H). Anal. Calcd for C19H19F3N4O: C, 60.63; H, 5.09; N, 14.89.
Found: C, 60.63; H, 5,69; N, 14.89.
General procedure for making α-hydroxy ester 183a-c (Procedure C): The α-amino acid (5
mmol) was dissolved in a mixture of water (10 mL) and acetic acid (40 mL) in a 250 mL flask.
5 mL of a 2 M aqueous solution of sodium nitrite (10 mmol, 2 equiv) was added slowly over 15
min at 0 ºC internal temperature. The reaction was warmed to room temperature and stirred
overnight. Once the reaction was finished (TLC ninhydrin), it was quenched with 5 ml of 2 M
methylamine solution in THF (10 mmol). THF was removed in vacuo. The aqueous residue was
acidified to pH ≤ 2.0 with 2 N aqueous HCl, and then extracted with ethyl acetate (100 mL × 3).
The combined extracts were washed with brine (100 mL) and dried over sodium sulfate.
Evaporation of the solvent gave a yellow solid, which was dissolved into DMF (15 mL). Sodium
bicarbonate (840.1 mg, 10 mmol, 2 equiv) and benzyl bromide (1.283 g, 7.5 mmol, 1.5 equiv)
were then added. The reaction mixture was stirred at room temperature overnight, diluted with
ethyl acetate (250 mL), washed with deionized water (150 mL) and brine (100 mL × 2)
subsequently, and dried over sodium sulfate. Evaporation of the solvent gave a yellow oil, which
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was subjected to silica gel column chromatography (Hexanes : EtOAc 10/1) to afford the product
as a colorless oil.
(S)-benzyl 2-hydroxy-3-phenylpropanoate (183a). Following procedure C, 839 mg (65%) of
product was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.13 – 7.38 (m, 10H),
5.18 (d, J = 1.6 Hz, 2H), 4.47 – 4.51 (m, 1H), 3.12 (dd, J = 14, 4.8 Hz, 1H), 2.98 (dd, J = 14, 6.4
Hz, 1H), 2.70 (d, J = 6.4 Hz, 1H).
(S)-benzyl 2-hydroxy-3-methylbutanoate (183b). Following procedure C, 720 mg (69%) of
product was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.35 – 7.37 (m, 5H),
5.22 (d, J = 7.2 Hz, 2H), 4.07 (q, J = 3.6 Hz, 1H), 2.67 (d, J = 6.4 Hz, 1H), 2.05 – 2.14 (m, 1H),
1.01 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H).
(S)-benzyl 2-hydroxy-4-methylpentanoate (183c). Following procedure C, 783 mg (70%) of
product was obtained as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.34 – 7.38 (m, 5H),
5.21 (d, J = 1.6 Hz, 2H), 4.21 – 4.26 (m, 1H), 2.61 (d, J = 6.0 Hz, 1H), 1.83 – 1.93 (m, 1H), 1.55
– 1.59 (m, 2H), 0.93 (dd, J = 6.8, 4.8 Hz, 6H).
(R)-benzyl 2-cyclohexyl-2-hydroxyacetate (183d). The (R)-2-amino-2-cyclohexylacetic acid
(786 mg, 5 mmol, 1 equiv) was dissolved in a mixture of water (30 mL) and acetic acid (50 mL)
in a 250 mL flask. Sodium nitrite (690 mg, 10 mmol, 2 equiv) was added in three portions over
15 min at 0 ºC. The reaction was warmed to room temperature and stirred for two days. Once
the reaction was finished (TLC ninhydrin), it was quenched with 5 ml of 2 M methylamine
solution in THF (10 mmol). THF was removed in vacuo. The aqueous residue was acidified to
pH ≤ 2.0 with 2 N aqueous HCl, and then extracted with ethyl acetate (100 mL × 3). The
combined extracts were washed with brine and dried over sodium sulfate. Evaporation of the
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solvent gave a yellow solid, which was dissolved in DMF (15 mL). Sodium bicarbonate (1.26 g,
15 mmol, 3 equiv) and benzyl bromide (2.56 g, 15 mmol, 3 equiv) were then added. The
reaction mixture was stirred at room temperature overnight, diluted with ethyl acetate (250 mL),
washed with deionized water (150 mL) and brine (100 mL × 2) subsequently, and dried over
sodium sulfate. Evaporation of the solvent gave a yellow oil, which was subjected to silica gel
column chromatography (Hexanes : EtOAc 10/1) to afford 388 mg (31%) of the product as a
colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.32 – 7.40 (m, 5H), 5.22 (s, 2H), 4.06 (dd, J = 6.4,
3.6 Hz, 1H), 2.63 (d, J = 6.4 Hz, 1H), 1.62 – 1.76 (m, 5H), 1.08 – 1.39 (m, 6H).
General procedure for making triflate 180a-d (Procedure D): 2,6-lutidine (468 mg, 4.37
mmol, 1.9 equiv) was added to a solution of the α-hydroxy ester (2.30 mmol, 1.0 equiv) in
dichloromethane (17 mL) at 0 °C. Triflic anhydride (1.103g, 3.91 mmol, 1.7 equiv) was added
and the mixture was stirred at 0 °C for 30 min until the reaction was completed (TLC). The
reaction mixture was diluted with diethyl ether (150 mL), washed with 3:1 brine: 1N aqueous
HCl (50 mL × 1, then 25 mL × 2) and dried over magnesium sulfate. Evaporation of the solvent
at room temperature afforded the triflate as a yellow or brown oil, which was stored in the
freezer until use.
(R)-benzyl 2-(N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2trifluoroacetamido)-3-phenylpropanoate (181a) Sodium hydride, 60% dispersion in mineral
oil (18 mg, 0.30 mmol, 1.2 equiv) was to a solution of (N-(4-(benzylamino)-1-isopropyl-1Hbenzo[d]imidazol-6-yl)-2,2,2-trifluoroacetamide (179; 94 mg, 0.25 mmol, 1.0 equiv) in THF (1
mL). This white suspension was stirred at room temperature for 30 min. A 0.25 M solution of
triflate (180a, 0.25 mmol, 1.0 equiv) in THF (1 mL) was added, and the stirring was continued
for 50 min. The mixture was diluted with ethyl acetate (20 mL), washed with brine (5 mL × 2),
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and dried over magnesium sulfate. Evaporation of the solvent gave a brown oil, which was
subjected to silica gel column chromatography (hexanes/EtOAc 1:1, 0.5% Et3N) to afford 36 mg
(23%) of product as a white solid. Rf 0.54 (CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (400
MHz, CDCl3): δ 7.73 (d, J = 1.2 Hz, 1H), 7.15 – 7.40 (m, 15H), 6.53 (s, 0.5H), 6.25 (s, 1H), 5.04
– 5.25 (m, 4H), 4.42 – 4.49 (m, 1H), 3.96 – 4.09 (m, 3H), 3.40 – 3.61 (m, 2H), 1.39 (dt, J = 23.6,
6,8 Hz, 6H).
(R)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)-3-phenylpropan-1-ol
(173a, scheme 35 synthesis). Sodium borohydride (33 mg, 0.57 mmol, 5 equiv) was added to a
solution of (R)-benzyl 2-(N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2trifluoroacetamido)-3-phenylpropanoate (181a, 70 mg, 0.114 mmol, 1equiv) in ethanol (1 mL) at
0 °C. The mixture was stirred at room temperature overnight, quenched with saturated aqueous
ammonium chloride (5 mL), and extracted with ethyl acetate (4 mL × 3). The combined extracts
were washed with brine (5 mL) and dried over sodium sulfate. Evaporation of the solvent gave a
brown solid, which was subjected to silica gel column chromatography (hexanes/EtOAc 1:3,
0.5% Et3N) to afford 37 mg (79%) of the final compound as a brown foam. Rf 0.02
(CH2Cl2/MeOH/NH4OH 100:5:0.1). 1H NMR (400 MHz, CDCl3): δ 7.63 (s, 1H), 7.20 – 7.42
(m, 5H), 7.13 (d, J = 6.8 Hz, 2H), 6.00 (s, 1H), 5.76 (d, J = 1.6 Hz, 1H), 5.31 (t, J = 5.2 Hz, 1H),
4.39 – 4.46 (m, 3H), 3.70 (d, J = 8.4 Hz, 2H), 4.47 (dd, J = 11.6, 6.8 Hz, 1H), 2.92 (dd, J = 13.6,
4.8 Hz, 1H), 2.81 (dd, J = 13.6, 7.2 Hz, 1H), 1.56 (dd, J = 6.4, 2.4 Hz, 6H).
(R)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)-4-methylpentan-1-ol
(182c). Sodium hydride, 60% dispersion in mineral oil (60 mg, 1.0 mmol, 2.0 equiv) was added
in 2 portions to a solution of (N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2trifluoroacetamide (179; 188 mg, 0.5 mmol, 1.0 equiv) in THF (2 mL). This white suspension
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was stirred at room temperature for 30 min. A 0.375 M solution of triflate (180c, 0.75 mmol,
1.5 equiv) in THF (2 mL) was added, and the stirring was continued for 70 min. The mixture
was diluted with ethyl acetate (40 mL), washed with brine (10 mL × 2), and dried over sodium
sulfate. Evaporation of the solvent gave a brown oil, which was dissolved in ethanol (5 mL).
Sodium borohydride (95 mg, 2.5 mmol) was added at 0 °C. The mixture was stirred at room
temperature overnight, quenched with saturated aqueous ammonium chloride (20 mL), and
extracted with ethyl acetate (15 mL × 3). The combined extracts were washed with brine and
dried over sodium sulfate. Evaporation of the solvent gave a brown oil, which was subjected to
silica gel column chromatography (hexanes/EtOAc 1:3, 0.5% Et3N) to afford 60 mg (31%) of the
final compound as a brown foam. 1H NMR (500 MHz, CDCl3): δ 7.60 (s, 1H), 7.22 – 7.41 (m,
5H), 5.99 (d, J = 2 Hz, 1H), 5.74 (d, J = 2.5 Hz, 1H), 5.25 (t, J = 5 Hz, 1H), 4.39 – 4.45 (m, 3H),
3.73 (dd, J = 3.9, 10.7 Hz, 1H), 3.49 – 3.54 (m, 1H), 3.43 (dd, J = 6.1, 10.7 Hz, 1H), 2.36 (br,
1H), 1.66 – 1.74 (m, 1H), 1.54 (dd, J = 2.5, 6.7 Hz, 6H), 1.31 – 1.45 (m, 2H), 0.89 (dd, J = 6.1,
10.7 Hz, 1H).
(R)-2-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-ylamino)-4-methylpentan-1-ol
(182d). Sodium hydride, 60% dispersion in mineral oil (90 mg, 1.5 mmol, 3.0 equiv) was added
in 2 portions to a solution of (N-(4-(benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yl)-2,2,2trifluoroacetamide (179; 188 mg, 0.5 mmol, 1.0 equiv) in THF (2 mL). This white suspension
was stirred at room temperature for 30 min. A 0.375 M solution of triflate (180d, 0.75 mmol,
1.5 equiv) in THF (2 mL) was added, and the stirring was continued for 70 min. The mixture
was diluted with ethyl acetate (40 mL), washed with brine (10 mL × 2), and dried over sodium
sulfate. Evaporation of the solvent gave a brown oil, which was dissolved in ethanol (5 mL).
Sodium borohydride (95 mg, 2.5 mmol) was added at 0 °C. The mixture was stirred at room
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temperature overnight, quenched with saturated aqueous ammonium chloride (20 mL), and
extracted with ethyl acetate (15 mL × 3). The combined extracts were washed with brine and
dried over sodium sulfate. Evaporation of the solvent gave a brown oil, which was subjected to
silica gel column chromatography (hexanes/EtOAc 1:1, 0.5% Et3N) to afford a white foam. This
was recrystallized from ethyl acetate and hexanes to afford 101 mg (37%) of a white solid. Rf
0.47 (CH2Cl2/MeOH/NH4OH 100:5:0.1). mp 133.7 – 143.2 °C. 1H NMR (400 MHz, CDCl3): δ
7.81 (d, J = 6 Hz, 1H), 7.23 – 7.34 (m, 10H), 6.64 (d, J = 7.6 Hz, 1H), 6.23 (d, J = 19.6 Hz, 1H),
5.48 (t, J = 5.2 Hz, 0.5H), 5.38 (t, J = 5.6 Hz, 0.5H), 5.10 (d, J = 1.6 Hz, 2H), 4.30 – 4.53 (m,
3H), 4.01 – 4.17 (m, 1H), 1.59 – 2.29 (m, 6H), 1.52 (dd, J = 16, 6.4 Hz, 3H), 1.43 (dd, J = 6.8,
12.4 Hz, 6H), 0.73 – 1.27 (m, 5H).
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Chapter 8
Appendix
Molecular modeling for 6-benzylbenzimidazole series
The designed ligands were bought to local energy minimum conformations and manually docked
using MOEdock into the putative ATP binding site on the X-ray crystal structure 1UNL. Then
the receptor/ligand complex was brought to an overall local energy minimum retaining the
backbone conformation of 1UNL. Ligands were inspected for reasonable interactions with the
enzyme surface and scored with a published scoring algorithm developed by the Madura lab16.
Compounds 120a,b were identified as having the most favorable interactions by the above
methods (Table 6 and Figure 34).
Table6. Results by Analysis with the Madura scoring algorithm. (Positive values represent favorable
interactions in units of kcal.)
Compound

van der
Waals

Electrostatics

Total
interaction

Interaction site

125a

12.55

‐3.128

9.427

cys83 ile10 leu133 asp86

(R)‐roscovitine

0

0

0

cys83 ile10 gln130

125b

‐6.58

12.33

5.76

cys83 ile10 leu133 asn131 gln130
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Figure 34. Proposed interactions of compounds 120a and 120b with CDK5/p25.

Molecular modeling for 6-aminobenzimidazole series
London dG scoring protocol:
London dG Scoring (default): The London dG scoring function estimates the free energy of
binding of the ligand from a given pose. The functional form is a sum of terms:
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where c represents the average gain/loss of rotational and translational entropy; Eflex is the energy
due to the loss of flexibility of the ligand (calculated from ligand topology only); fHB measures
geometric imperfections of hydrogen bonds and takes a value in [0,1]; cHB is the energy of an
ideal hydrogen bond; fM measures geometric imperfections of metal ligations and takes a value in
[0,1]; cM is the energy of an ideal metal ligation; and Di is the desolvation energy of atom i. The
difference in desolvation energies is calculated according to the formula

where A and B are the protein and/or ligand volumes with atom i belonging to volume B; Ri is the
solvation radius of atom i (taken as the OPLS-AA van der Waals sigma parameter plus 0.5
Angstrom); and ci is the desolvation coefficient of atom i. The coefficients {c, cHB, cM, ci} were
fitted from ~400 x-ray crystal structures of protein-ligand complexes with available experimental
pKi data. Atoms are categorized into ~12 atom types for the assignment of the ci coefficients.
The triple integrals are approximated using Generalized Born integral formulas.
New scoring was conducted with the Lig-X protocol without modification. Multiple
conformations examined. Amide backbone was fixed. Final complex was minimized. London
dG scoring used to estimate pKi.
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Table 7. New scoring results.

Compound

pKi
7.434

7.461

NH

7.838

N
R

N

7.943

(R)‐roscovitine

8.029
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Figure 35 Proposed interactions of compounds 173a,b and 181c with CDK5/p25.
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The X-ray crystal structure of compound 146a:

Figure 36. The ORTEP drawing of the X‐ray crystal structure of compound 146a.
Kindly provided by Dr. Omar Stewart.

Biological assay for CDK5 project
The biological testing of these compounds was conducted in the laboratory of Dr. Laurent Meijer
(CNRS Station Biologique, Roscoff, France).
Activities of CDK1, CDK2, CDK5, GSK3β, CK1, DyrK1A and Erk2 were assayed in 25 mM
Mops Buffer (pH 7.2) with 60 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, and 1 mM
DTT.
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The protein histone H1 (Sigma; 1 mg/ml) was used as the substrate, in the presence of 15 µm [γ33

P] ATP (3,000 Ci/mmol; 1 mCi/ml) to a final volume of 30 µl. After a 10 minute incubation

period at 30 °C, 25 µl aliquots of supernatant were removed and spotted onto 2.5 x 3 cm pieces
of Whatman P81 phosphocellulose paper. After 20 seconds the filter paper was washed five
times (for at least 5 min. each time) with a solution of 10 ml phosphoric acid/liter of water. The
wet filter paper was then counted in the presence of 1 ml ACS (Amersham) scintillation fluid to
determine the degree of substrate phosphorylation.
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